STOCK TITAN

Regional Health Properties swings to $879K Q3 loss

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Regional Health Properties, Inc. (RHEP) reported third-quarter revenue of $25.014 million, compared with $15.138 million a year earlier, and nine-month revenue of $70.618 million, versus $32.385 million. It recorded a third-quarter net loss of $879,000, compared with $3.382 million of net income, and a nine-month net loss of $2.891 million, compared with $671,000 of net income.

For the first nine months, operating activities generated $2.496 million of cash, compared with $994,000 used a year earlier. At September 30, cash was $1.651 million, total cash and restricted cash was $4.893 million, and notes payable and other debt was $42.191 million. Southland-related USDA and SBA notes remained subject to forbearance arrangements through February 1, 2027; the company said it was otherwise in compliance with its credit-facility covenants.

A prospective purchaser sent a nonbinding letter of intent on October 27 proposing approximately $4.0 million for Meadowood and its operating business. RHEP recorded a $459,000 impairment after estimating fair value less selling costs at approximately $3.8 million. Management concluded it is probable the company can meet obligations due within one year after the statements are issued.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

How the balance works

Positive

  • Moderate pointNine-month revenue: $70.618 million, compared with $32.385 million a year earlier.
  • Moderate pointOperating cash flow: $2.496 million provided, versus $994,000 used in the prior-year period.

Negative

  • Major pointNine-month net loss: $2.891 million, compared with $671,000 of net income a year earlier.
  • Moderate pointSouthland’s $5.0 million USDA and $0.8 million SBA notes remain under forbearance.

Filing Explained

Shareholders approved an expanded stock plan on January 5: it permits 775,000 shares for awards, with 351,000 still available; 135,000 restricted stock units remained unvested at September 30, 2026, so any resulting share issuance would dilute existing holders’ ownership percentages.

Third-quarter revenue $25.014 million Three months ended September 30, 2026; $15.138 million in 2025
Nine-month revenue $70.618 million Nine months ended September 30, 2026; $32.385 million in 2025
Third-quarter net income (loss) $(879,000) Three months ended September 30, 2026; $3.382 million net income in 2025
Nine-month net income (loss) $(2.891) million Nine months ended September 30, 2026; $671,000 net income in 2025
Cash provided by operating activities $2.496 million Nine months ended September 30, 2026; $994,000 used in 2025
Cash and restricted cash $4.893 million As of September 30, 2026
Notes payable and other debt $42.191 million As of September 30, 2026, net of deferred financing costs and unamortized discount
Meadowood impairment loss $459,000 Recognized in the three and nine months ended September 30, 2026
forbearance arrangements financial
"subject to the forbearance arrangements"
A forbearance arrangement is a temporary agreement between a borrower and a lender that allows the borrower to pause, reduce, or delay loan payments or modify other loan terms when facing financial strain. Think of it as a pause button on repayments that gives the borrower breathing room; for investors, it can lower near-term default risk and preserve cash flow but also signals financial stress and can change expected returns and creditworthiness.
nonbinding letter of intent financial
"received a nonbinding letter of intent from a prospective purchaser"
A nonbinding letter of intent is a written summary of the basic terms two parties expect to agree on in a future transaction, similar to a handshake that lists price, structure and key steps but does not legally force the deal to happen. It matters to investors because it signals serious interest, can affect a company’s stock price and often starts due diligence and formal negotiations, while still allowing either side to walk away.
assets held for sale financial
"assets classified as held for sale"
Assets held for sale are things a company has decided to sell and has reclassified on its balance sheet to show they are being marketed rather than used in daily operations — like putting a house on the market instead of living in it. This matters to investors because these items are measured based on expected sale proceeds (which can reveal likely gains or losses), stop being treated as regular operating assets, and signal upcoming cash inflows or a change in strategy that can affect the company’s financial health and stock value.
Level 2 inputs financial
"valuation assumptions ... represent Level 2 inputs"
straight-line rent receivables financial
"creating straight-line rent receivables"
anti-dilutive securities financial
"excluded from the computation, because they would have been anti-dilutive"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was RHEP’s revenue in the third quarter of 2026?

RHEP reported third-quarter revenue of $25.014 million, compared with $15.138 million for the third quarter of 2025. Nine-month revenue was $70.618 million in 2026 and $32.385 million in 2025.

How much cash did RHEP generate from operations in the first nine months of 2026?

Operating activities provided $2.496 million of cash in the nine months ended September 30, 2026, compared with $994,000 used in the same period of 2025.

What are the terms of RHEP’s Southland loan forbearance?

The Southland-related USDA note had principal of $5,000,000 and the SBA note had principal of $800,000. Under the agreements, monthly principal and interest payments continue, interest accrues, and the remaining balances are due at the end of the forbearance period on February 1, 2027.

What is the proposed price for RHEP’s Meadowood property and business?

A prospective purchaser’s nonbinding letter of intent proposed a purchase price of approximately $4.0 million for Meadowood and its related operating business. RHEP estimated fair value less selling costs at approximately $3.8 million and recorded a $459,000 impairment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
--12-310001004724Q3falseone year http://fasb.org/srt/2026#ChiefExecutiveOfficerMember http://fasb.org/srt/2026#PresidentMemberhttp://fasb.org/us-gaap/2026#RevenueFromContractWithCustomerExcludingAssessedTaxhttp://fasb.org/us-gaap/2026#RevenueFromContractWithCustomerExcludingAssessedTaxhttp://fasb.org/us-gaap/2026#RevenueFromContractWithCustomerExcludingAssessedTaxhttp://fasb.org/us-gaap/2026#RevenueFromContractWithCustomerExcludingAssessedTaxhttp://fasb.org/us-gaap/2026#RevenueFromContractWithCustomerExcludingAssessedTaxhttp://fasb.org/us-gaap/2026#RevenueFromContractWithCustomerExcludingAssessedTaxhttp://fasb.org/us-gaap/2026#RevenueFromContractWithCustomerExcludingAssessedTaxhttp://fasb.org/us-gaap/2026#RevenueFromContractWithCustomerExcludingAssessedTaxhttp://fasb.org/us-gaap/2026#RevenueFromContractWithCustomerExcludingAssessedTaxhttp://fasb.org/us-gaap/2026#RevenueFromContractWithCustomerExcludingAssessedTax0001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtHUDMemberrhep:GlenvueHealthAndRehabilitationMemberrhep:NewpointCapitalMember2025-12-310001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtUSDAMemberrhep:SouthlandHealthcareMemberrhep:CadenceBankNAMember2025-12-310001004724us-gaap:SubsequentEventMember2026-10-270001004724us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2024-12-310001004724us-gaap:RestrictedStockMemberrhep:EmployeeMember2025-07-012025-09-300001004724srt:MaximumMember2026-09-300001004724us-gaap:RetainedEarningsMember2025-12-310001004724us-gaap:RetainedEarningsMember2025-01-012025-03-310001004724us-gaap:DiscontinuedOperationsHeldforsaleMember2026-07-012026-09-300001004724us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2026-07-012026-09-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesBPreferredStockMember2025-07-012025-09-300001004724rhep:MountainTraceRehabMemberus-gaap:SeniorDebtObligationsMemberrhep:CommunityBankMemberrhep:SeniorDebtUSDAMember2025-12-310001004724us-gaap:SeniorDebtObligationsMemberrhep:SumterValleyMemberrhep:SeniorDebtHUDMemberrhep:KeyBankMember2025-12-310001004724us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2026-03-310001004724rhep:EmployeeMemberus-gaap:EmployeeStockOptionMember2025-07-012025-09-300001004724us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2025-07-012025-09-300001004724rhep:EmployeeMemberus-gaap:EmployeeStockOptionMember2025-01-012025-09-300001004724us-gaap:SeriesBPreferredStockMember2025-12-310001004724us-gaap:SeriesBPreferredStockMember2026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtSBAMemberrhep:CadenceBankNAMemberrhep:SouthlandHealthcareMember2025-12-310001004724rhep:SumterCountySouthCarolinaMemberus-gaap:SubsequentEventMember2026-10-012026-10-310001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtUSDAMember2025-12-310001004724us-gaap:CommonStockMember2025-06-300001004724rhep:FirstInsuranceFundingMemberrhep:OtherDebtMember2025-12-310001004724rhep:SeniorDebtSBAMember2026-09-300001004724us-gaap:LeaseAgreementsMember2025-07-012025-09-300001004724rhep:MeadowoodMemberrhep:ExchangeBankOfAlabamaMemberrhep:SeniorDebtOtherMortgageIndebtednessMember2026-09-300001004724us-gaap:RetainedEarningsMember2026-03-310001004724rhep:RentalRevenueMember2026-07-012026-09-300001004724rhep:PharmacyIntangiblesMember2025-12-310001004724us-gaap:CorporateMember2025-07-012025-09-300001004724us-gaap:PreferredStockMember2026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtSBAMemberrhep:SouthlandHealthcareMemberrhep:CadenceBankNAMemberus-gaap:PrimeRateMember2026-01-012026-09-300001004724rhep:HealthcareServicesMember2026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:HearthAndCareOfGreenfieldMemberrhep:SeniorDebtHUDMemberrhep:NewpointCapitalMember2026-01-012026-09-300001004724srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2026-01-012026-09-300001004724rhep:SunLinkMemberrhep:MergerAgreementMember2025-08-142025-08-140001004724rhep:RangeOneMember2026-01-012026-09-300001004724us-gaap:HealthCarePatientServiceMember2025-07-012025-09-300001004724rhep:FirstInsuranceFundingMemberrhep:OtherDebtMember2026-09-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesBPreferredStockMember2025-06-300001004724rhep:SunLinkMember2026-07-012026-09-300001004724rhep:RoutineDebtMember2026-09-300001004724rhep:SeniorDebtHUDMember2025-12-310001004724rhep:PharmacySegmentMember2025-12-310001004724rhep:EmployeeRestrictedStockUnitsMember2026-01-012026-09-300001004724us-gaap:CommonStockMember2025-07-012025-09-3000010047242025-12-310001004724rhep:CavalierSeniorLivingMemberrhep:OtherDebtMember2025-12-310001004724rhep:BedLicensesIncludedInPropertyAndEquipmentMember2025-12-310001004724rhep:AFCOInsuranceMemberrhep:OtherDebtMember2026-09-300001004724rhep:KeyBankMemberrhep:OtherDebtMember2026-09-300001004724rhep:TreasuryStockPreferredAndCommonStockMember2025-03-3100010047242025-01-310001004724us-gaap:RetainedEarningsMember2026-04-012026-06-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtHUDMemberrhep:WoodlandManorMemberrhep:NewpointCapitalMember2026-01-012026-09-300001004724rhep:TreasuryStockPreferredAndCommonStockMember2024-12-3100010047242026-06-300001004724us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-09-300001004724rhep:SeriesASeriesBAndSeriesDPreferredStockMember2026-09-300001004724rhep:PharmacyRevenuesMember2026-07-012026-09-300001004724rhep:MeadowoodFacilityMember2026-09-300001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-04-012025-06-300001004724us-gaap:SeniorDebtObligationsMemberrhep:AutumnBreezeFacilityMemberrhep:SeniorDebtHUDMemberrhep:KeyBankMember2026-09-300001004724us-gaap:RetainedEarningsMember2024-12-310001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesAPreferredStockMember2025-06-300001004724us-gaap:SeriesBPreferredStockMember2025-07-012025-09-300001004724us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2026-09-300001004724us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesBPreferredStockMember2026-07-012026-09-300001004724rhep:BedLicensesSeparableMember2025-12-310001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesAPreferredStockMember2024-12-310001004724rhep:SeniorDebtUSDAMember2025-12-310001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtSBAMember2026-09-300001004724rhep:BedLicensesIncludedInPropertyAndEquipmentMember2026-01-012026-09-300001004724rhep:BoardStockOptionsMemberrhep:NonemployeeMember2026-07-012026-09-300001004724srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2026-01-012026-09-300001004724rhep:RealEstateServicesSegmentMember2026-07-012026-09-300001004724us-gaap:SeriesDPreferredStockMemberrhep:SunLinkMember2025-08-142025-08-140001004724us-gaap:CommonStockMember2025-01-012025-03-310001004724rhep:FirstHorizonBankMemberrhep:OtherDebtMember2026-01-012026-09-300001004724rhep:PharmacyRevenuesMember2026-01-012026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtSBAMemberrhep:SouthlandHealthcareMemberrhep:CadenceBankNAMember2026-09-300001004724rhep:SeniorDebtUSDAMember2026-09-300001004724rhep:RealEstateSegmentMember2025-12-310001004724rhep:PurchasePriceAllocationMember2025-01-012025-09-300001004724us-gaap:CommonStockMember2026-01-012026-09-300001004724rhep:BondDebtMember2026-09-300001004724us-gaap:RestrictedStockMemberrhep:EmployeeMember2025-01-012025-09-300001004724us-gaap:CommonStockMemberrhep:SunLinkMember2025-07-012025-09-300001004724us-gaap:SeriesAPreferredStockMember2026-07-012026-09-300001004724rhep:FirstHorizonBankMemberrhep:OtherDebtMember2026-09-300001004724rhep:PharmacyIntangibles-TradeNameMember2026-09-300001004724rhep:CovingtonOhioMember2026-01-012026-09-300001004724us-gaap:SeriesBPreferredStockMember2026-07-012026-09-300001004724rhep:MortageRefinancingWithExchangeBankMemberus-gaap:SubsequentEventMember2026-10-010001004724rhep:RangeOneMember2026-09-3000010047242025-03-310001004724rhep:SBANoteMember2026-02-270001004724rhep:PharmacySegmentMember2026-01-012026-09-300001004724rhep:PharmacySegmentMember2026-09-300001004724rhep:SeniorDebtHUDMember2026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:HearthAndCareOfGreenfieldMemberrhep:SeniorDebtHUDMemberrhep:NewpointCapitalMember2025-12-310001004724us-gaap:RetainedEarningsMemberus-gaap:SeriesBPreferredStockMember2025-07-012025-09-300001004724us-gaap:CommonStockMember2026-09-300001004724rhep:PharmacyServiceMember2025-01-012025-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtHUDMember2025-12-3100010047242025-07-012025-09-300001004724rhep:MortageRefinancingWithExchangeBankMemberus-gaap:SubsequentEventMember2026-11-052026-11-050001004724rhep:SeniorDebtOtherMortgageIndebtednessMember2025-12-310001004724rhep:PharmacyIntangiblesMember2026-01-012026-09-300001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-06-300001004724us-gaap:HealthCarePatientServiceMember2025-01-012025-09-300001004724rhep:SeniorDebtBondsMember2025-12-310001004724rhep:SunLinkMemberus-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-07-012025-09-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesBPreferredStockMember2026-04-012026-06-3000010047242024-12-310001004724us-gaap:EmployeeStockOptionMember2026-09-300001004724rhep:SeniorDebtUSDAMembersrt:MaximumMember2026-01-012026-09-300001004724rhep:FacilityMember2026-09-300001004724rhep:HealthcareServicesSegmentMember2026-07-012026-09-300001004724us-gaap:SeriesDPreferredStockMember2026-09-300001004724us-gaap:EquipmentMembersrt:MinimumMember2026-09-300001004724rhep:AspireRegionalPartnersMember2026-01-012026-09-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesAPreferredStockMember2026-06-300001004724rhep:HealthcareServicesSegmentMember2025-07-012025-09-3000010047242026-02-272026-02-270001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesBPreferredStockMember2025-03-310001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2026-01-012026-03-310001004724rhep:PromissoryNoteMembersrt:MinimumMember2026-01-012026-09-300001004724rhep:BedLicensesSeparableMember2026-09-300001004724us-gaap:DiscontinuedOperationsHeldforsaleMember2026-01-012026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:HearthAndCareOfGreenfieldMemberrhep:SeniorDebtHUDMemberrhep:NewpointCapitalMember2026-09-300001004724rhep:SouthlandsMaturingDebtMember2026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:AutumnBreezeFacilityMemberrhep:SeniorDebtHUDMemberrhep:KeyBankMember2025-12-310001004724rhep:AFCOInsuranceMemberrhep:OtherDebtMember2025-12-310001004724rhep:CityOfSpringfieldMemberus-gaap:BondsMemberrhep:EaglewoodCareCenterMemberrhep:BondsSeriesAMember2026-01-012026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtUSDAMember2026-09-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesAPreferredStockMember2025-09-300001004724srt:MinimumMemberrhep:SeniorDebtUSDAMember2026-01-012026-09-300001004724rhep:MeadowoodMemberrhep:ExchangeBankOfAlabamaMemberrhep:SeniorDebtOtherMortgageIndebtednessMember2025-12-310001004724us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2024-12-310001004724rhep:HealthcareServicesSegmentMember2025-01-012025-09-300001004724rhep:TreasuryStockPreferredAndCommonStockMember2025-12-310001004724us-gaap:RetainedEarningsMember2026-07-012026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtHUDMemberrhep:GlenvueHealthAndRehabilitationMemberrhep:NewpointCapitalMember2026-09-300001004724us-gaap:CommonStockMember2026-03-310001004724us-gaap:SeniorDebtObligationsMemberrhep:ThePavilionCareCenterMemberrhep:SeniorDebtHUDMemberrhep:NewpointCapitalMember2025-12-310001004724rhep:SeriesBCumulativeRedeemablePreferredSharesMember2026-01-012026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtHUDMemberrhep:GeorgetownHealthMemberrhep:NewpointCapitalMember2026-01-012026-09-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesAPreferredStockMember2025-03-310001004724us-gaap:RestrictedStockMember2026-09-300001004724us-gaap:CommonStockMember2025-09-300001004724rhep:NonemployeeMember2025-07-012025-09-300001004724rhep:SeniorDebtUSDAMember2026-01-012026-09-3000010047242026-01-050001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesBPreferredStockMember2025-12-310001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesAPreferredStockMember2025-12-310001004724us-gaap:RestrictedStockMemberrhep:EmployeeMember2026-07-012026-09-300001004724rhep:PharmacyRevenuesMemberrhep:PharmacyServiceMember2025-01-012025-09-300001004724rhep:BoardStockOptionsMemberrhep:NonemployeeMember2025-01-012025-09-300001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2026-09-300001004724us-gaap:SeriesAPreferredStockMember2026-01-012026-09-300001004724us-gaap:RestrictedStockMember2026-01-012026-09-300001004724us-gaap:CommonStockMember2026-09-300001004724rhep:BoardStockOptionsMemberrhep:NonemployeeMember2025-07-012025-09-300001004724us-gaap:RestrictedStockMemberrhep:EmployeeMember2026-01-012026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SumterValleyMemberrhep:SeniorDebtHUDMemberrhep:KeyBankMember2026-01-012026-09-300001004724rhep:SunLinkMember2026-09-300001004724us-gaap:SeriesDPreferredStockMember2025-12-310001004724us-gaap:CorporateMember2026-01-012026-09-300001004724us-gaap:EquipmentMembersrt:MaximumMember2026-01-012026-09-300001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-01-012025-03-310001004724rhep:KeyBankMember2022-12-302022-12-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtHUDMemberrhep:GeorgetownHealthMemberrhep:NewpointCapitalMember2025-12-310001004724us-gaap:EquipmentMember2026-09-300001004724rhep:EmployeeMember2026-07-012026-09-300001004724rhep:AFCOInsuranceMemberrhep:OtherDebtMember2026-01-012026-09-300001004724us-gaap:RestrictedStockUnitsRSUMemberrhep:EmployeeMember2026-01-012026-09-300001004724us-gaap:RetainedEarningsMemberus-gaap:SeriesBPreferredStockMember2026-04-012026-06-300001004724rhep:KeyBankMemberrhep:OtherDebtMember2025-12-310001004724us-gaap:LeaseAgreementsMember2026-07-012026-09-300001004724rhep:TreasuryStockPreferredAndCommonStockMember2026-09-300001004724rhep:RealEstateServicesSegmentMember2025-01-012025-09-300001004724us-gaap:EmployeeStockOptionMember2026-01-012026-09-300001004724rhep:PharmacyRevenuesMemberrhep:PharmacyServiceMember2025-07-012025-09-300001004724rhep:TreasuryStockPreferredAndCommonStockMember2025-09-300001004724rhep:MeadowoodFacilityMember2025-12-310001004724rhep:SeniorDebtOtherMortgageIndebtedness1Member2025-12-310001004724rhep:NonemployeeMember2026-07-012026-09-300001004724rhep:PharmacyRevenuesMember2025-07-012025-09-3000010047242026-04-012026-06-300001004724us-gaap:RetainedEarningsMemberus-gaap:SeriesBPreferredStockMember2026-07-012026-09-300001004724us-gaap:CommonStockMember2026-06-300001004724rhep:PurchasePriceAllocationMember2025-07-012025-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:AutumnBreezeFacilityMemberrhep:SeniorDebtHUDMemberrhep:KeyBankMember2026-01-012026-09-3000010047242025-01-012025-09-300001004724us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2026-04-012026-06-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtHUDMemberrhep:WoodlandManorMemberrhep:NewpointCapitalMember2025-12-310001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2026-04-012026-06-300001004724us-gaap:SeriesBPreferredStockMember2026-01-012026-09-300001004724rhep:BedLicensesIncludedInPropertyAndEquipmentMember2026-07-012026-09-300001004724rhep:RentalRevenueMember2025-07-012025-09-300001004724us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-09-300001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-03-310001004724us-gaap:BuildingAndBuildingImprovementsMember2025-12-310001004724srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2026-09-300001004724rhep:PharmacyServiceMember2026-01-012026-09-300001004724us-gaap:EmployeeStockOptionMember2026-01-012026-09-300001004724us-gaap:SeriesAPreferredStockMember2025-01-012025-09-300001004724us-gaap:RetainedEarningsMember2026-09-300001004724us-gaap:EquipmentMembersrt:MinimumMember2026-01-012026-09-300001004724rhep:OtherDebtMember2026-09-300001004724us-gaap:RetainedEarningsMember2025-06-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesBPreferredStockMember2026-09-300001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2026-03-310001004724rhep:EmployeeMember2025-07-012025-09-300001004724us-gaap:CommonStockMember2026-07-012026-09-300001004724us-gaap:LeaseAgreementsMember2025-01-012025-09-300001004724rhep:BedLicensesIncludedInPropertyAndEquipmentMember2025-07-012025-09-300001004724rhep:SunLinkMember2026-01-012026-09-300001004724us-gaap:EquipmentMember2025-12-310001004724rhep:PharmacyRevenuesMember2025-01-012025-09-300001004724us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2026-06-300001004724srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2026-09-300001004724us-gaap:CorporateMember2025-01-012025-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtHUDMemberrhep:GlenvueHealthAndRehabilitationMemberrhep:NewpointCapitalMember2026-01-012026-09-300001004724rhep:NonEmployeeStockOptionMember2026-01-012026-09-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesBPreferredStockMember2024-12-310001004724rhep:OtherDebtMember2025-12-310001004724rhep:MountainTraceRehabMemberus-gaap:SeniorDebtObligationsMemberrhep:CommunityBankMemberrhep:SeniorDebtUSDAMember2026-01-012026-09-300001004724rhep:RentalRevenueMember2025-01-012025-09-300001004724rhep:SunLinkMember2025-08-142025-08-140001004724rhep:MortageRefinancingWithExchangeBankMemberus-gaap:SubsequentEventMember2031-10-052031-10-050001004724us-gaap:SeniorDebtObligationsMemberrhep:ThePavilionCareCenterMemberrhep:SeniorDebtHUDMemberrhep:NewpointCapitalMember2026-09-300001004724rhep:TreasuryStockPreferredAndCommonStockMember2026-03-310001004724rhep:SeriesBCumulativeRedeemablePreferredSharesMember2025-01-310001004724rhep:FirstInsuranceFundingMemberrhep:OtherDebtMember2026-01-012026-09-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesAPreferredStockMember2026-03-310001004724us-gaap:SeriesDPreferredStockMember2026-01-012026-09-3000010047242026-09-300001004724us-gaap:EmployeeStockOptionMember2025-12-310001004724rhep:HealthcareServicesSegmentMember2026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtSBAMemberrhep:CadenceBankNAMemberrhep:SouthlandHealthcareMember2026-01-012026-09-300001004724us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2025-06-3000010047242026-07-012026-09-300001004724rhep:KeyBankMemberrhep:OtherDebtMember2026-01-012026-09-300001004724us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2026-03-310001004724rhep:PharmacyServicesMember2026-09-300001004724rhep:RealEstateSegmentMember2026-01-012026-09-300001004724us-gaap:RetainedEarningsMember2025-07-012025-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:ThePavilionCareCenterMemberrhep:SeniorDebtHUDMemberrhep:NewpointCapitalMember2026-01-012026-09-300001004724rhep:BedLicensesIncludedInPropertyAndEquipmentMember2026-09-300001004724us-gaap:CommonStockMember2025-03-310001004724rhep:SeniorDebtHUDMember2026-01-012026-09-300001004724us-gaap:SeriesAPreferredStockMember2025-12-310001004724rhep:MountainTraceRehabMemberus-gaap:SeniorDebtObligationsMemberrhep:CommunityBankMemberrhep:SeniorDebtUSDAMemberus-gaap:PrimeRateMember2026-01-012026-09-300001004724us-gaap:SubsequentEventMemberus-gaap:SeriesBPreferredStockMember2026-10-012026-10-010001004724rhep:PharmacyIntangibles-TradeNameMember2025-12-310001004724us-gaap:CommonStockMember2026-04-012026-06-300001004724rhep:HealthcareServicesSegmentMember2026-01-012026-09-300001004724us-gaap:SeriesDPreferredStockMember2026-07-012026-09-300001004724us-gaap:HealthCarePatientServiceMemberrhep:HealthcareServicesSegmentMember2025-01-012025-09-300001004724us-gaap:RestrictedStockMember2025-12-310001004724us-gaap:LeaseAgreementsMember2025-12-310001004724us-gaap:RestrictedStockUnitsRSUMemberrhep:EmployeeMember2025-01-012025-09-300001004724rhep:SeniorDebtSBAMember2025-12-310001004724rhep:CavalierSeniorLivingMemberrhep:OtherDebtMember2026-01-012026-09-300001004724rhep:TreasuryStockPreferredAndCommonStockMember2026-06-300001004724us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2025-03-310001004724rhep:EmployeeMemberus-gaap:EmployeeStockOptionMember2026-01-012026-09-300001004724us-gaap:HealthCarePatientServiceMemberrhep:HealthcareServicesSegmentMember2026-07-012026-09-300001004724us-gaap:RetainedEarningsMember2025-03-310001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-12-310001004724us-gaap:RetainedEarningsMember2026-06-300001004724rhep:SeriesASeriesBAndSeriesDPreferredStockMember2025-12-310001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesAPreferredStockMember2026-09-300001004724us-gaap:HealthCarePatientServiceMemberrhep:HealthcareServicesSegmentMember2025-07-012025-09-300001004724rhep:PharmacyRevenuesMemberrhep:PharmacyServiceMember2026-01-012026-09-300001004724us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2025-12-310001004724rhep:MortageRefinancingWithExchangeBankMemberus-gaap:SubsequentEventMember2026-10-012026-10-010001004724us-gaap:RetainedEarningsMemberus-gaap:SeriesBPreferredStockMember2026-01-012026-03-310001004724rhep:PharmacyIntangiblesMember2026-07-012026-09-300001004724us-gaap:HealthCarePatientServiceMember2026-01-012026-09-300001004724us-gaap:RestrictedStockUnitsRSUMemberrhep:EmployeeMember2025-07-012025-09-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesBPreferredStockMember2025-09-300001004724rhep:HealthcareServicesSegmentMember2025-12-310001004724rhep:SunLinkMember2025-08-140001004724us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001004724rhep:OtherDebtMember2025-12-310001004724rhep:TreasuryStockPreferredAndCommonStockMember2025-06-300001004724rhep:SeniorDebtOtherMortgageIndebtedness1Member2026-09-300001004724rhep:CovingtonOhioMember2025-01-012025-12-310001004724rhep:RealEstateServicesMember2025-12-310001004724rhep:EmployeeMember2025-01-012025-09-3000010047242026-03-3100010047242026-01-012026-09-300001004724us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2026-07-012026-09-300001004724us-gaap:RetainedEarningsMember2025-04-012025-06-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtHUDMember2026-09-300001004724rhep:USDANoteMember2026-02-270001004724rhep:PharmacyIntangiblesMember2026-09-300001004724rhep:MountainTraceRehabMemberus-gaap:SeniorDebtObligationsMemberrhep:CommunityBankMemberrhep:SeniorDebtUSDAMember2026-09-300001004724rhep:MeadowoodMemberus-gaap:LineOfCreditMemberrhep:ExchangeBankOfAlabamaMember2026-01-012026-09-300001004724rhep:CityOfSpringfieldMemberus-gaap:BondsMemberrhep:EaglewoodCareCenterMemberrhep:BondsSeriesAMember2026-09-300001004724rhep:RealEstateServicesSegmentMember2026-01-012026-09-300001004724rhep:SeniorDebtOtherMortgageIndebtednessMember2026-09-3000010047242025-04-012025-06-3000010047242025-01-012025-03-310001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-07-012025-09-300001004724us-gaap:RetainedEarningsMember2025-09-300001004724us-gaap:LandMember2025-12-310001004724rhep:MeadowoodMemberus-gaap:LineOfCreditMemberrhep:ExchangeBankOfAlabamaMemberrhep:SeniorDebtOtherMortgageIndebtednessMember2026-09-300001004724rhep:RealEstateServicesSegmentMember2025-07-012025-09-300001004724us-gaap:RestrictedStockUnitsRSUMemberrhep:EmployeeMember2026-07-012026-09-300001004724rhep:MeadowoodMemberus-gaap:LineOfCreditMemberrhep:ExchangeBankOfAlabamaMember2026-09-300001004724us-gaap:HealthCarePatientServiceMember2026-07-012026-09-300001004724rhep:SeniorDebtBondsMember2026-09-300001004724rhep:MeadowoodMemberrhep:ExchangeBankOfAlabamaMember2026-09-300001004724us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2025-09-300001004724rhep:HealthcareServicesMember2025-12-310001004724rhep:RealEstateSegmentMember2026-09-300001004724rhep:BoardStockOptionsMemberrhep:NonemployeeMember2026-01-012026-09-300001004724rhep:PharmacyServicesMember2025-12-3100010047242026-11-120001004724us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2025-12-310001004724us-gaap:BuildingAndBuildingImprovementsMember2026-09-300001004724us-gaap:CommonStockMember2024-12-310001004724rhep:NonemployeeMember2025-01-012025-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtHUDMemberrhep:GeorgetownHealthMemberrhep:NewpointCapitalMember2026-09-300001004724rhep:EmployeeMemberus-gaap:EmployeeStockOptionMember2026-07-012026-09-300001004724rhep:RentalRevenueMember2026-01-012026-09-300001004724us-gaap:SeriesAPreferredStockMember2026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SouthlandHealthcareMemberrhep:SeniorDebtUSDAMemberrhep:CadenceBankNAMember2026-01-012026-09-300001004724rhep:OtherDebtMember2026-09-300001004724rhep:BedLicensesIncludedInPropertyAndEquipmentMember2025-01-012025-09-300001004724rhep:HealthcareServicesAndPharmacyServicesPatientAccountsReceivableMember2026-09-300001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-12-310001004724rhep:PharmacyServiceMember2025-07-012025-09-300001004724us-gaap:CorporateMember2026-07-012026-09-300001004724us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2026-06-300001004724us-gaap:CommonStockMemberrhep:SunLinkMember2025-08-142025-08-140001004724rhep:PharmacyRevenuesMemberrhep:PharmacyServiceMember2026-07-012026-09-3000010047242025-06-300001004724us-gaap:AccruedLiabilitiesMember2026-09-300001004724us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2026-09-300001004724rhep:NonemployeeMember2026-01-012026-09-300001004724us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2025-03-310001004724rhep:MeadowoodMemberrhep:ExchangeBankOfAlabamaMember2026-01-012026-09-300001004724us-gaap:AccruedLiabilitiesMember2025-12-310001004724us-gaap:SeniorDebtObligationsMemberrhep:SouthlandHealthcareMemberrhep:CadenceBankNAMemberrhep:SeniorDebtUSDAMember2026-09-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesBPreferredStockMember2026-03-3100010047242026-01-012026-03-310001004724us-gaap:SeniorDebtObligationsMemberrhep:SumterValleyMemberrhep:SeniorDebtHUDMemberrhep:KeyBankMember2026-09-300001004724us-gaap:CommonStockMember2025-07-012025-09-300001004724us-gaap:RestrictedStockUnitsRSUMember2025-12-310001004724us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2026-01-012026-03-310001004724us-gaap:RestrictedStockUnitsRSUMember2026-09-300001004724us-gaap:CommonStockMemberrhep:SunLinkMember2025-08-140001004724us-gaap:CommonStockMember2025-04-012025-06-300001004724us-gaap:SeriesBPreferredStockMember2025-01-012025-09-300001004724rhep:RealEstateServicesMember2026-09-300001004724rhep:SeniorDebtSBAMember2026-01-012026-09-300001004724us-gaap:EquipmentMembersrt:MaximumMember2026-09-300001004724rhep:CavalierSeniorLivingMemberrhep:OtherDebtMember2026-09-300001004724rhep:PharmacyServiceMember2026-07-012026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtSBAMember2025-12-310001004724us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2025-09-300001004724us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2026-06-3000010047242025-09-300001004724us-gaap:LandMember2026-09-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesBPreferredStockMember2026-01-012026-03-310001004724rhep:CityOfSpringfieldMemberus-gaap:BondsMemberrhep:EaglewoodCareCenterMemberrhep:BondsSeriesAMember2025-12-310001004724us-gaap:CommonStockMember2025-12-310001004724us-gaap:HealthCarePatientServiceMemberrhep:HealthcareServicesSegmentMember2026-01-012026-09-300001004724rhep:EmployeeMember2026-01-012026-09-300001004724rhep:SBANoteMember2026-02-272026-02-270001004724us-gaap:LeaseAgreementsMember2026-09-300001004724us-gaap:CommonStockMember2025-01-012025-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:CadenceBankNAMemberrhep:SouthlandHealthcareMemberrhep:SeniorDebtUSDAMemberus-gaap:PrimeRateMember2026-01-012026-09-300001004724us-gaap:RetainedEarningsMember2026-01-012026-03-310001004724us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2025-06-300001004724us-gaap:SeriesAPreferredStockMember2025-07-012025-09-300001004724us-gaap:SeriesDPreferredStockMemberrhep:SunLinkMember2025-08-140001004724us-gaap:LeaseAgreementsMember2026-01-012026-09-300001004724us-gaap:SeniorDebtObligationsMemberrhep:SeniorDebtHUDMemberrhep:WoodlandManorMemberrhep:NewpointCapitalMember2026-09-300001004724us-gaap:PreferredStockIncludingAdditionalPaidInCapitalMemberus-gaap:SeriesBPreferredStockMember2026-06-300001004724rhep:PromissoryNoteMembersrt:MaximumMember2026-01-012026-09-30rhep:Facilityxbrli:purexbrli:sharesrhep:Credit_instrumentrhep:Operatoriso4217:USDxbrli:sharesrhep:Segmentiso4217:USDrhep:State

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to ______

Commission File Number 001-33135

 

Regional Health Properties, Inc.

(Exact name of registrant as specified in its charter)

 

Georgia

 

81-5166048

(State or other jurisdiction

of incorporation)

 

(I.R.S. Employer

Identification Number)

 

1050 Crown Pointe Parkway, Suite 720, Atlanta, GA 30338

(Address of principal executive offices)

(678) 869-5116

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.:

 

Large accelerated filer

☐

 

 

Accelerated filer

☐

Non-accelerated filer

☒

 

 

Smaller reporting company

☒

 

 

 

 

Emerging growth company

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

As of November 12, 2026 the registrant had 3,924,677 shares of common stock, no par value, outstanding.

 

 


 

Regional Health Properties, Inc.

Form 10-Q

Table of Contents

Page
Number

Part I.

FINANCIAL INFORMATION

 

Item 1.

Financial Statements (unaudited)

3

Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025

3

Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2026 and 2025

4

Consolidated Statements of Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2026 and 2025

5

Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025

7

Notes to Consolidated Financial Statements

9

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

31

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

43

Item 4.

Controls and Procedures

43

 

Part II.

OTHER INFORMATION

 

 

Item 1.

Legal Proceedings

43

Item 1A.

Risk Factors

43

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

44

Item 3.

Defaults upon Senior Securities

44

Item 4.

Mine Safety Disclosures

44

Item 5.

Other Information

44

Item 6.

Exhibits

44

 

Signatures

47

 

2


 

Part I. Financial Information

Item 1. Financial Statements

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Amounts in 000's)

 

 

September 30,
2026 (Unaudited)

 

 

December 31,
2025

 

ASSETS

 

 

 

 

 

 

Cash

 

$

1,651

 

 

$

3,013

 

Restricted cash

 

 

2,243

 

 

 

1,631

 

Accounts receivable, net of allowances of $1,256 and $727

 

 

10,643

 

 

 

8,025

 

Inventory

 

 

1,464

 

 

 

1,354

 

Notes receivable

 

 

564

 

 

 

644

 

Prepaid expenses and other

 

 

1,413

 

 

 

1,623

 

Total current assets

 

 

17,978

 

 

 

16,290

 

Property and equipment, net

 

 

35,025

 

 

 

35,805

 

Assets held for sale, net

 

 

3,811

 

 

 

4,207

 

Restricted cash

 

 

999

 

 

 

1,420

 

Intangible assets

 

 

4,584

 

 

 

4,660

 

Other assets

 

 

3,521

 

 

 

3,842

 

Goodwill

 

 

1,585

 

 

 

1,585

 

Total assets

 

$

67,503

 

 

$

67,809

 

LIABILITIES AND EQUITY (DEFICIT)

 

 

 

 

 

 

Accounts payable

 

$

7,819

 

 

$

6,986

 

Accrued expenses

 

 

9,792

 

 

 

7,888

 

Other liabilities

 

 

2,035

 

 

 

867

 

Debt related to assets held for sale, net

 

 

3,027

 

 

 

3,001

 

Current portion of long-term debt, net

 

 

5,319

 

 

 

5,414

 

Total current liabilities

 

 

27,992

 

 

 

24,156

 

Long-term debt, net - less current maturities

 

 

33,845

 

 

 

34,738

 

Operating lease obligation

 

 

2,040

 

 

 

2,325

 

Other liabilities

 

 

1,544

 

 

 

1,550

 

Total liabilities

 

 

65,421

 

 

 

62,769

 

Preferred stock, Series D, no par values, 1,420 shares authorized; 1,406 shares issued and outstanding at September 30, 2026 and December 31, 2025.

 

 

4,691

 

 

 

4,691

 

Stockholders' equity:

 

 

 

 

 

 

Common stock and additional paid-in capital, no par value; 55,000 shares authorized; 3,936 issued and 3,925 outstanding at September 30, 2026 and 3,946 issued and 3,935 outstanding at December 31, 2025.

 

 

67,550

 

 

 

67,296

 

Preferred stock, no par value; 5,000 shares authorized (including amounts authorized for Series A, Series B and Series D); shares issued and outstanding designated separately

 

 

 

 

 

 

Preferred stock, Series A, no par value; 560 shares authorized, issued and outstanding at September 30, 2026 and December 31, 2025, with a redemption amount $426 at September 30, 2026 and December 31, 2025

 

 

426

 

 

 

426

 

Preferred stock, Series B, no par value; 2,812 shares authorized; 1,690 and 1,741 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively, with a redemption amount $13,960 and $14,382 at September 30, 2026 and December 31, 2025, respectively

 

 

13,960

 

 

 

14,382

 

Accumulated deficit

 

 

(84,567

)

 

 

(81,777

)

    Accumulated other comprehensive earnings

 

 

22

 

 

 

22

 

Total stockholders' equity (deficit)

 

 

(2,609

)

 

 

349

 

Total liabilities, Series D preferred stock and stockholders' equity (deficit)

 

$

67,503

 

 

$

67,809

 

See accompanying notes to unaudited consolidated financial statements.

3


 

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Amounts in 000's except per share amounts)

(Unaudited)

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

Patient care revenues

$

14,714

 

 

$

9,831

 

 

$

41,430

 

 

$

24,247

 

Rental revenues

 

798

 

 

 

1,303

 

 

 

2,459

 

 

 

4,134

 

Pharmacy revenues

 

9,502

 

 

 

4,004

 

 

 

26,729

 

 

 

4,004

 

Total revenues

 

25,014

 

 

 

15,138

 

 

 

70,618

 

 

 

32,385

 

Expenses:

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

5,838

 

 

 

2,470

 

 

 

16,419

 

 

 

2,470

 

Patient care expense

 

11,035

 

 

 

8,639

 

 

 

31,404

 

 

 

20,224

 

Facility rent expense

 

248

 

 

 

197

 

 

 

729

 

 

 

552

 

Depreciation and amortization

 

785

 

 

 

547

 

 

 

2,264

 

 

 

1,351

 

General and administrative expense

 

6,570

 

 

 

3,713

 

 

 

19,785

 

 

 

8,375

 

Loss on lease termination

 

-

 

 

 

-

 

 

 

-

 

 

 

303

 

Credit loss expense

 

210

 

 

 

166

 

 

 

607

 

 

 

636

 

Gain on operations transfer

 

-

 

 

 

-

 

 

 

-

 

 

 

(106

)

Total expenses, excluding impairment

 

24,686

 

 

 

15,732

 

 

 

71,208

 

 

 

33,805

 

Impairment loss on assets held for sale

 

459

 

 

 

-

 

 

 

459

 

 

 

-

 

Income (loss) from operations

 

(131

)

 

 

(594

)

 

 

(1,049

)

 

 

(1,420

)

Other (income) expense:

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

576

 

 

 

751

 

 

 

1,665

 

 

 

2,019

 

Loss (gain) on bargain purchase

 

78

 

 

 

(5,311

)

 

 

78

 

 

 

(5,311

)

Loss on disposal of assets

 

11

 

 

 

-

 

 

 

19

 

 

 

-

 

Other (income) expense, net

 

83

 

 

 

584

 

 

 

80

 

 

 

1,201

 

Total other (income) expense, net

 

748

 

 

 

(3,976

)

 

 

1,842

 

 

 

(2,091

)

Net income (loss)

 

(879

)

 

 

3,382

 

 

 

(2,891

)

 

 

671

 

Preferred stock dividends

 

-

 

 

 

-

 

 

 

-

 

 

 

(603

)

Deemed contribution related to Preferred Series B purchases

 

28

 

 

 

278

 

 

 

101

 

 

 

278

 

Net income (loss) attributable to Regional Health Properties, Inc. common stockholders

$

(851

)

 

$

3,660

 

 

$

(2,790

)

 

$

346

 

Net income (loss) per share of common stock attributable to Regional Health Properties, Inc.

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted

$

(0.22

)

 

$

1.17

 

 

$

(0.71

)

 

$

0.14

 

Weighted average shares of common stock outstanding:

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted

 

3,925

 

 

 

3,125

 

 

 

3,929

 

 

 

2,425

 

 

See accompanying notes to unaudited consolidated financial statements.

4


 

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

(Amounts in 000's)

(Unaudited)

 

 

 

Outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares of
Common
Stock

 

 

Shares of
Preferred
Stock A

 

 

Shares of
Preferred
Stock B

 

 

Shares of Treasury Stock

 

 

Common
Stock and
Additional
Paid-in
Capital

 

 

Preferred Stock A, no par value

 

 

Preferred Stock B, no par value

 

 

Accumulated
Deficit

 

 

Accumulated other comprehensive earnings

 

 

Total

 

Balance, December 31, 2025

 

 

3,935

 

 

 

560

 

 

 

1,741

 

 

 

(11

)

 

$

67,296

 

 

$

426

 

 

$

14,382

 

 

$

(81,777

)

 

$

22

 

 

$

349

 

Repurchase of Preferred B Shares

 

 

—

 

 

 

—

 

 

 

(30

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(250

)

 

 

64

 

 

 

—

 

 

 

(186

)

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

96

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

96

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(1,221

)

 

 

—

 

 

 

(1,221

)

Balances, March 31, 2026

 

 

3,935

 

 

 

560

 

 

 

1,711

 

 

 

(11

)

 

$

67,392

 

 

$

426

 

 

$

14,132

 

 

$

(82,934

)

 

$

22

 

 

$

(962

)

Repurchase of Preferred B Shares

 

 

—

 

 

 

—

 

 

 

(5

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(41

)

 

 

9

 

 

 

—

 

 

 

(32

)

Forfeitures of stock-based awards

 

 

(10

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

73

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

73

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(791

)

 

 

—

 

 

 

(791

)

Balances, June 30, 2026

 

 

3,925

 

 

 

560

 

 

 

1,706

 

 

 

(11

)

 

$

67,465

 

 

$

426

 

 

$

14,091

 

 

$

(83,716

)

 

$

22

 

 

$

(1,712

)

Repurchase of Preferred B Shares

 

 

—

 

 

 

—

 

 

 

(16

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(131

)

 

 

28

 

 

 

—

 

 

 

(103

)

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

85

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

85

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(879

)

 

 

—

 

 

 

(879

)

Balances, September 30, 2026

 

 

3,925

 

 

 

560

 

 

 

1,690

 

 

 

(11

)

 

$

67,550

 

 

$

426

 

 

$

13,960

 

 

$

(84,567

)

 

$

22

 

 

$

(2,609

)

 

5


 

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

(Amounts in 000's)

(Unaudited)

 

 

 

Outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares of
Common
Stock

 

 

Shares of
Preferred
Stock A

 

 

Shares of
Preferred
Stock B

 

 

Shares of Treasury Stock

 

 

Common
Stock and
Additional
Paid-in
Capital

 

 

Preferred Stock A, no par value

 

 

Preferred Stock B, no par value

 

 

Accumulated
Deficit

 

 

Accumulated other comprehensive earnings

 

 

Total

 

Balance, December 31, 2024

 

 

1,879

 

 

 

560

 

 

 

2,252

 

 

 

(11

)

 

$

63,173

 

 

$

426

 

 

$

18,602

 

 

$

(85,120

)

 

 

—

 

 

$

(2,919

)

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

22

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

22

 

Common stock issued in connection with Preferred Stock Series B dividends

 

 

250

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

603

 

 

 

—

 

 

 

—

 

 

 

(603

)

 

 

—

 

 

 

—

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(1,262

)

 

 

—

 

 

 

(1,262

)

Balances, March 31, 2025

 

 

2,129

 

 

 

560

 

 

 

2,252

 

 

 

(11

)

 

$

63,798

 

 

$

426

 

 

$

18,602

 

 

$

(86,985

)

 

$

—

 

 

$

(4,159

)

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

25

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

25

 

Restricted stock issuance

 

 

65

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Exercise of stock options

 

 

48

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

129

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

129

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(1,449

)

 

 

—

 

 

 

(1,449

)

Balances, June 30, 2025

 

 

2,242

 

 

 

560

 

 

 

2,252

 

 

 

(11

)

 

$

63,952

 

 

$

426

 

 

$

18,602

 

 

$

(88,434

)

 

$

—

 

 

$

(5,454

)

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

124

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

124

 

Restricted stock issuance

 

 

100

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Repurchase of Preferred B Shares

 

 

—

 

 

 

—

 

 

 

(366

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(3,026

)

 

 

278

 

 

 

—

 

 

 

(2,748

)

Acquisition of SunLink (shares issued, effective date Aug. 14, 2025)

 

 

1,593

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

3,158

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

3,158

 

Net income

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

3,382

 

 

 

—

 

 

 

3,382

 

Balances, September 30, 2025

 

 

3,935

 

 

 

560

 

 

 

1,886

 

 

 

(11

)

 

$

67,234

 

 

$

426

 

 

$

15,576

 

 

$

(84,774

)

 

$

—

 

 

$

(1,538

)

 

See accompanying notes to unaudited consolidated financial statements.

6


 

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in 000's)

(Unaudited)

 

 

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

Cash flows from operating activities:

 

 

 

 

 

 

Net income (loss)

 

$

(2,891

)

 

$

671

 

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

2,264

 

 

 

1,351

 

Stock-based compensation expense

 

 

254

 

 

 

171

 

Rent expense less than cash paid

 

 

355

 

 

 

(40

)

Rent revenue less than (in excess) of cash received

 

 

227

 

 

 

(339

)

Amortization of deferred financing costs, debt discounts and premiums

 

 

45

 

 

 

56

 

Loss (gain) on bargain purchase

 

 

78

 

 

 

(5,311

)

Loss on lease termination

 

 

-

 

 

 

303

 

Gain on operations transfer

 

 

-

 

 

 

(106

)

Loss on disposal of fixed assets

 

 

19

 

 

 

-

 

Impairment loss on assets held for sale

 

 

459

 

 

 

-

 

Credit loss expense

 

 

607

 

 

 

636

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(3,225

)

 

 

(1,923

)

Prepaid expenses and other assets

 

 

515

 

 

 

(243

)

Inventory

 

 

(110

)

 

 

(36

)

Accounts payable and accrued expenses

 

 

2,737

 

 

 

3,718

 

Other liabilities

 

 

1,162

 

 

 

98

 

Net cash provided by (used in) operating activities

 

 

2,496

 

 

 

(994

)

Cash flows from investing activities:

 

 

 

 

 

 

Cash acquired from merger

 

 

-

 

 

 

5,975

 

Purchase of property and equipment

 

 

(1,568

)

 

 

(643

)

Net cash (used in) provided by investing activities

 

 

(1,568

)

 

 

5,332

 

Cash flows from financing activities:

 

 

 

 

 

 

Payment of senior debt

 

 

(1,307

)

 

 

(1,293

)

Payment of other debt

 

 

(749

)

 

 

(584

)

Repurchase of Preferred B Shares

 

 

(321

)

 

 

(2,748

)

Proceeds from the exercise of stock options

 

 

-

 

 

 

128

 

Proceeds from other debt

 

 

278

 

 

 

679

 

Net cash used in financing activities

 

 

(2,099

)

 

 

(3,818

)

Net change in cash and restricted cash

 

 

(1,171

)

 

 

520

 

Cash and restricted cash, beginning

 

 

6,064

 

 

 

3,472

 

Cash and restricted cash, ending

 

$

4,893

 

 

$

3,992

 

 

7


 

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in 000's)

(Unaudited)

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

Cash interest paid

 

$

1,668

 

 

$

1,285

 

Supplemental disclosure of non-cash activities:

 

 

 

 

 

 

Vendor-financed insurance

 

 

225

 

 

 

614

 

Preferred stock dividends paid in common stock

 

 

—

 

 

 

603

 

Issuance of Series D Preferred Shares

 

 

—

 

 

 

4,691

 

Common shares issued for merger

 

 

—

 

 

 

3,158

 

 

See accompanying notes to unaudited consolidated financial statements.

8


 

REGIONAL HEALTH PROPERTIES, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

September 30, 2026

NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Regional Health Properties, Inc. (the "Company") is a healthcare company that owns, operates and invests in healthcare real estate and operating businesses focused on long-term care, senior housing and pharmacy services. Historically, the Company operated primarily as a healthcare real estate platform that leased skilled nursing and senior housing facilities to third-party operators under long-term triple-net lease arrangements. Over time, and particularly following recent strategic initiatives and acquisitions, the Company has evolved toward a more integrated healthcare operating model that combines healthcare real estate ownership with the direct operation of healthcare facilities and related healthcare services.

Through its subsidiaries, the Company owns and operates skilled nursing and senior housing communities that provide a range of healthcare and residential services, including sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative therapy, memory care, Alzheimer’s and dementia care and senior living services. In addition to operating healthcare facilities, the Company owns healthcare real estate that is leased to third-party operators pursuant to triple-net lease arrangements.

Since August 14, 2025, as part of the merger with SunLink Health Systems, the Company also acquired a pharmacy business located in Crowley, Louisiana that provides retail pharmacy services, institutional pharmacy services and durable medical equipment. The pharmacy business expands the Company’s participation across the care continuum and provides additional operating capabilities that complement its healthcare facility operations.

The Company currently operates across six states, with the majority of its facilities located in the Southeastern United States. The Company has four reportable segments: (i) Healthcare Services, which consists of the operation of skilled nursing and senior housing communities; (ii) Pharmacy Services, which consists of retail and institutional pharmacy services and durable medical equipment; (iii) Real Estate Services, which consists of the leasing and subleasing of healthcare properties to third-party tenants; and (iv) Corporate, consists of general and administrative expenses, These segments reflect the Company’s evolution from a healthcare landlord into a more diversified owner-operator with both real estate and operating capabilities.

As of September 30, 2026, the Company’s common stock, Series A Redeemable Preferred Stock, 12.5% Series B Cumulative Redeemable Preferred Shares, and Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares were quoted on the OTCQB under the symbols “RHEP,” “RHEPA,” “RHEPB,” and “RHEPZ,” respectively.

Basis of Presentation

The accompanying condensed consolidated financial statements ("consolidated financial statements") are prepared in conformity with United States ("U.S.") generally accepted accounting principles ("GAAP") in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"). The accompanying condensed consolidated financial statements are unaudited and should be read in conjunction with the 2025 audited consolidated financial statements and notes thereto, which are included in the 2025 Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC") on April 2, 2026.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported results of operations during the reporting period. Significant estimates include patient care revenues, rent revenues, allowance for doubtful accounts and credit losses, contractual allowances for Medicaid, Medicare, and managed care reimbursements, deferred tax valuation allowance, valuation of goodwill and other long-lived assets, and cash flow projections. Actual results could differ materially from those estimates.

 

9


 

Revenue Recognition and Allowance for Credit Losses

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, and ASC Topic 842, Leases, as applicable to the nature of the underlying revenue-generating activity. Revenue is recognized in an amount that reflects the consideration the Company expects to receive in exchange for goods or services transferred to customers or, in the case of lease arrangements, in accordance with the terms of the applicable lease agreements. The Company’s revenues are derived primarily from (i) patient care and other healthcare services provided through its Healthcare Services segment, (ii) pharmacy goods and services and durable medical equipment provided through its Pharmacy Services segment, and (iii) rental income from healthcare properties leased to third-party operators through its Real Estate Services segment. For revenue recognized under Topic 606, the Company evaluates the collectability of receivables and records allowances for credit losses and other valuation adjustments in accordance with ASC Topic 326, Financial Instruments—Credit Losses.

Patient Care Revenue. Revenue from the Healthcare Services segment is derived from services rendered to residents and patients at the Company’s skilled nursing and senior housing communities. The Company receives payment for these services from several sources, including: (i) the federal government under the Medicare program administered by the Centers for Medicare & Medicaid Services (“CMS”), (ii) state governments under their respective Medicaid and similar programs, (iii) commercial insurers and managed care organizations, and (iv) private pay residents and other individual patients. The transaction price is based on established billing rates, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients, and other implicit price concessions. The Company recognizes revenue in the amount it expects to be entitled to receive in exchange for the services provided, including variable consideration for estimated retroactive reimbursement adjustments, if any. Performance obligations are satisfied over time as services are rendered to residents and patients. Amounts assessed as uncollectible from residents and patients are generally recorded as implicit price concessions and reflected as a direct reduction of patient care revenue.

Pharmacy Services Revenue. Revenue from the Pharmacy Services segment is derived primarily from the sale of pharmacy products and the provision of pharmacy-related services, including retail pharmacy services, institutional pharmacy services, and durable medical equipment. Revenue is recognized when control of the promised goods or services is transferred to the customer, generally on the date the applicable goods are dispensed or delivered and services are provided. Each prescription claim or sale represents a separate performance obligation. Significant portions of Pharmacy Services revenue are reimbursed by the federal Medicare Part D program and, to a lesser extent, state Medicaid programs and other third-party insurance payors. The Company records Pharmacy Services revenue at amounts billable to patients or payors, adjusted at the time of revenue recognition for estimates of variable consideration arising from anticipated differences between billed charges and amounts expected to be reimbursed. Accordingly, Pharmacy Services revenue and related receivables are reported at the net amount the Company expects to ultimately realize from patients, governmental programs, and other third-party payors.

Rental Revenue. Revenue from the Real Estate Services segment is recognized in accordance with ASC Topic 842, Leases. The Company’s triple-net leases generally provide for fixed rental payments and may include periodic and determinable increases in rent. Rental revenue is recognized on a straight-line basis over the non-cancelable lease term when collectability of substantially all lease payments is probable. The recognition of rental income on a straight-line basis may result in revenues recognized in advance of contractual cash receipts, creating straight-line rent receivables that are included in other assets on the consolidated balance sheets. If collectability of lease payments is no longer considered probable, the Company ceases recognition of rental income on a straight-line basis, limits future rental revenue recognition to cash received, and writes off or reserves against any existing straight-line rent receivables or other related balances, as appropriate.

Receivables and Allowance for Credit Losses. The Company measures financial assets carried at amortized cost, including trade accounts receivable, tenant receivables, straight-line rent receivables, and certain other financing-related receivables, at the net amount expected to be collected in accordance with ASC Topics 326 and 842.

In estimating expected credit losses, the Company evaluates relevant available information, including historical collection experience, the age of receivables, current collection trends, the financial condition and credit quality of patients, customers, tenants, and payors, the nature and level of any collateral or guarantees, and current and reasonable and supportable forecasts of future economic conditions. Expected credit losses are measured over the contractual life of the asset, adjusted for expected prepayments when appropriate.

For patient care receivables in the Healthcare Services segment, the Company considers the payer mix, the aging of receivables, historical collections, and expected reimbursements from Medicare, Medicaid, managed care, and private-pay sources. Amounts due from residents and patients that are not expected to be collected are generally treated as implicit price concessions and recorded as reductions of patient care revenue. To the extent a receivable is established and collection subsequently

10


 

becomes not probable due to a change in circumstances, the Company records an allowance for credit losses or credit loss expense, as appropriate.

For Pharmacy Services receivables, the Company evaluates concession allowances and expected credit losses based on historical collection trends, customer and payor mix, the age and nature of receivables, and current and expected future economic conditions. Pharmacy accounts receivable are presented net of estimated variable consideration and expected credit losses, such that the reported balance reflects the amount expected to be ultimately collected.

For Real Estate receivables, including straight-line rent receivables and working capital or other tenant-related receivables, the Company assesses collectability based on the tenant’s payment history, financial condition, the strength of any guarantors, the value of underlying collateral, lease-level operating performance, and broader economic conditions. If facts and circumstances indicate that amounts due may not be collectible, the Company records an allowance for credit losses or, if collectability of lease payments is no longer probable, adjusts rental revenue recognition prospectively to a cash basis.

Changes in estimates regarding variable consideration, contractual adjustments, implicit price concessions, or expected credit losses are recognized in the period in which the change in estimate becomes known.

Activity in the allowance for credit losses in the Pharmacy segment for the periods presented included the following:

Pharmacy

 

 

 

(Amounts in 000’s)

 

 

 

December 31, 2025 balance

 

$

255

 

Concession allowances expense

 

 

64

 

Write offs

 

 

(11

)

September 30, 2026 balance

 

$

308

 

 

Activity in the allowance for credit losses in the Real Estate Services segment for the periods presented included the following:

Real Estate

 

 

 

(Amounts in 000’s)

 

 

 

December 31, 2025 balance

 

$

71

 

Credit loss expense

 

 

13

 

Write offs

 

 

(13

)

September 30, 2026 balance

 

$

71

 

Activity in the allowance for credit losses in the Healthcare segment for periods presented included the following:

Healthcare

 

 

 

(Amounts in 000’s)

 

 

 

December 31, 2025 balance

 

$

401

 

Credit loss expense

 

 

594

 

Write offs

 

 

(118

)

September 30, 2026 balance

 

$

877

 

 

11


 

The following table presents the Company's Accounts receivable, net of allowance for the periods presented:

(Amounts in 000’s)

 

September 30,
2026

 

 

December 31,
2025

 

Gross receivables

 

 

 

 

 

 

Pharmacy Services

 

$

3,496

 

 

$

3,024

 

Real Estate Services

 

 

683

 

 

 

679

 

Healthcare Services

 

 

7,720

 

 

 

5,049

 

Subtotal

 

 

11,899

 

 

 

8,752

 

Allowance

 

 

 

 

 

 

Pharmacy Services

 

 

(308

)

 

 

(255

)

Real Estate Services

 

 

(71

)

 

 

(71

)

Healthcare Services

 

 

(877

)

 

 

(401

)

Subtotal

 

 

(1,256

)

 

 

(727

)

Accounts receivable, net of allowance

 

$

10,643

 

 

$

8,025

 

Inventory

As of September 30, 2026 and December 31, 2025, the Company had approximately $1.5 million and $1.4 million, respectively, in inventory of the Pharmacy Services segment. Inventory consists of pharmacy supplies, which are stated at the lower of cost (standard cost method), or net realizable value. Use of this method does not result in a material difference from the methods required by GAAP.

Prepaid Expenses and Other

As of September 30, 2026 and December 31, 2025, the Company had approximately $1.4 million and $1.6 million, respectively, in prepaid expenses and other, which primarily relate to insurance for the facilities we operate, directors’ and officers’ insurance, and mortgage insurance premiums.

Notes Receivable

Notes receivable are initially recognized when amounts previously recorded as accounts receivable are converted into promissory notes that evidence an unconditional obligation to pay a specified principal amount, generally together with interest, under defined repayment terms. Promissory notes are executed as an alternative to accounts receivable to formalize payment arrangements with customers. The Company's payment terms vary based on the specific facts and circumstances of each arrangement; however, promissory notes generally have maturities ranging from one to three years.

The Company evaluates outstanding notes receivable for expected credit losses at each reporting date. In estimating expected credit losses, management considers a variety of factors, including, but not limited to, payment history and current payment status, the financial condition and ability of the customer to repay, collateral or other credit enhancements, historical loss experience, and current and expected economic conditions, as applicable. We may establish reserves, accept modified payment terms, or book direct write-offs for any estimated credit loss with generally corresponding charge to credit loss expense in our Consolidated Statements of Operations and Comprehensive Loss. Subsequent changes in our estimate of credit losses may result in a corresponding increase or decrease to the credit loss expense in our Consolidated Statements of Operations and Comprehensive Loss.

Based on its evaluation as of September 30, 2026, management concluded that no allowance for expected credit losses on notes receivable was necessary, as all outstanding balances were considered collectible. Accordingly, no allowance for credit losses has been recorded related to notes receivable. The Company will continue to monitor the collectability of these balances each reporting period and will record an allowance for expected credit losses if warranted by changes in facts and circumstances.

Assets Held for Sale and Discontinued Operations

The Company may decide to sell properties that are held for use. The Company records these properties as assets held for sale when management has committed to a plan to sell the assets, actively seeks a buyer for the assets, and the consummation of the sale is considered probable and is expected within one year. Assets classified as held for sale are reported at the lower of their carrying value or their fair value, less estimated costs to sell. When the carrying value exceeds the fair value, less estimated costs to sell, an impairment expense is recognized. The Company estimates fair value, less estimated closing costs, based on

12


 

similar real estate sales transactions. These valuation assumptions are based on the three-level valuation hierarchy for fair value measurement and represent Level 2 and 3 inputs. Level 2 inputs are quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets in markets that are not active; and inputs other than quoted prices. Level 3 inputs are unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. See Note 6 – Assets Held for Sale for additional details on assets held for sale as of September 30, 2026 and December 31, 2025. Any debt related to assets held for sale or sold during the period are classified as debt related to assets held for sale for the current and prior periods presented in the accompanying consolidated financial statements.

Assets held for sale are presented as discontinued operations in all periods presented if the disposition represents a strategic shift that has, or will have, a major effect on the Company's financial position or results of operations. This includes the net gain (or loss) upon disposal of property held for sale, the property's operating results, depreciation and interest expense.

Accounts Payable

The following table presents the Company's Accounts payable for the periods presented:

(Amounts in 000’s)

 

September 30,
2026

 

 

December 31,
2025

 

Accounts payable

 

 

 

 

 

 

Pharmacy Services

 

$

1,542

 

 

$

956

 

Real Estate Services

 

 

1,186

 

 

 

615

 

Healthcare Services

 

 

5,091

 

 

 

5,415

 

Total Accounts payable

 

$

7,819

 

 

$

6,986

 

Other Liabilities

As of September 30, 2026 and December 31, 2025, the Company had approximately $2.0 million and $0.9 million, respectively in short-term other liabilities, which mainly represent short-term operating lease obligations.

 

As of September 30, 2026 and December 31, 2025, the Company had approximately $1.5 million and $1.6 million, respectively in long-term other liabilities, consisting of security lease deposits and sublease improvement funds.

Leases and Leasehold Improvements

The Company leases certain facilities and equipment in the normal course of business. At the inception of each lease, the Company performs an evaluation to determine whether the lease should be classified as an operating lease or finance lease. As of September 30, 2026, the Company's leased facility is accounted for as an operating lease. For operating leases that contain scheduled rent increases, the Company records rent expense on a straight-line basis over the term of the lease. Leasehold improvements are amortized over the shorter of the useful life of the asset or the lease term.

The Company assesses any new contracts or modification of contracts in accordance with ASC 842, Leases, to determine the existence of a lease and its classification. We are reporting revenues and expenses for real estate taxes and insurance where the lessee has not made those payments directly to a third party in accordance with their respective leases with us.

Insurance

The Company maintains insurance for professional and general liability claims for its Healthcare Services segment and Pharmacy segments and maintains coverage amounts that are required by its mortgage lenders. The Company elects to maintain a high deductible policy for workers' compensation. In addition, the Company maintains certain other insurance programs, including commercial general liability, property, casualty, directors’ and officers’ liability, crime, and employment practices liability.

Earnings Per Share

Basic earnings per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the respective period. Diluted earnings per share is similar to basic earnings per share except that the net income or loss is adjusted by the impact of the weighted-average number of shares of common stock outstanding including potentially dilutive securities (such as options, warrants and non-vested common stock)

13


 

when such securities are not anti-dilutive. Potentially dilutive securities from options, warrants and unvested restricted shares are calculated in accordance with the treasury stock method, which assumes that proceeds from the exercise of all options and warrants with exercise prices exceeding the average market value are used to repurchase common stock at market value. The incremental shares remaining after the proceeds are exhausted represent the potentially dilutive effect of the securities.

Securities outstanding that were excluded from the computation, because they would have been anti-dilutive were as follows:

 

 

 

 

(Share amounts in 000’s)

 

September 30,
2026

 

 

September 30,
2025

 

Restricted stock units - employee

 

 

135

 

 

 

—

 

Stock options - employee

 

 

135

 

 

 

—

 

Stock options - non employee

 

 

15

 

 

 

—

 

Total anti-dilutive securities

 

 

285

 

 

 

—

 

For further information regarding the Company's Equity Plans, see Note 12 - Stock Based Compensation.

New Accounting Pronouncements Issued But Not Yet Effective

In November 2024, the FASB issued ASU 2024-03, Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03), which requires disclosure of incremental income statement expense information on an annual and interim basis, primarily through enhanced disclosures of specified costs and expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that ASU 2024-03 will have on its consolidated financial statement disclosures.

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270), which aims to: (i) specify form and content choices for interim financial statements and accompanying notes; (ii) add a comprehensive list of required disclosures from numerous Codification Topics to Topic 270; and (iii) introduce a disclosure principle requiring events since the end of the previous annual reporting period to be disclosed if they materially affect the entity. ASU 2025-11 is effective for interim periods in fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that ASU 2025-11 will have on its consolidated financial statement disclosures.

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company's financial statements.

NOTE 2. LIQUIDITY

Overview

The Company’s liquidity profile is influenced by the operating performance and working capital needs of its Healthcare Services and Pharmacy Services segments, as well as rent collections, tenant performance and refinancing activity within its Real Estate Services segment. In 2025, the expansion of operated facilities increased the Company’s use of working capital, particularly accounts receivable, payroll-related expenditures and other operating costs, while the Real Estate Services segment continued to provide rental income and asset sale proceeds. As of September 30, 2026, the Company held approximately $1.7 million in unrestricted cash and $10.6 million in net accounts receivable, primarily comprised of Healthcare Services and Pharmacy Services patient accounts receivable.

The Company also experienced changes in its listing status in 2025. Until February 5, 2025, the Company’s common stock and Series A Preferred Stock were listed on the NYSE American under the ticker symbols “RHE” and “RHE-PA,” respectively. Trading was suspended on that date due to noncompliance with listing standards. On June 11, 2025, the NYSE American formally delisted both securities. They now trade on the OTCQB under the symbols “RHEP” and “RHEPA,” respectively. Trading on the OTC Markets presents challenges, including reduced liquidity, wider bid-ask spreads, limited analyst coverage and greater regulatory burdens on broker-dealers, which may further discourage trading activity. These limitations could depress trading prices and negatively impact the Company’s ability to raise capital through equity or debt offerings.

14


 

Short-term Liquidity

Management expects that the Company’s short-term liquidity requirements over the twelve months following the issuance of these unaudited condensed consolidated financial statements will be funded primarily through collections of patient and rent accounts receivable, refinancing activity, including refinancing related to the Southland facility, additional debt borrowings and proceeds from the sale of assets classified as held for sale. The Company has committed to a plan to sell assets classified as held for sale to generate additional liquidity in support of operations and potential investment opportunities. See Note 6 – Assets Held for Sale.

During the nine months ended September 30, 2026, the Company generated $2.5 million of cash in operating activities. Operating cash flows were primarily affected by working capital investments associated with the assumption of operations at Autumn Breeze, which was partially offset by non-cash adjustments. Management continues to focus on collections of aged patient receivables and on stabilizing the operating performance of the Company’s Healthcare Services and Pharmacy Services segments. The Company’s short-term liquidity continues to be affected by the transition of certain facilities from leased to operated status, which has increased working capital requirements, including payroll, supplies and patient receivables.

The Company’s future short-term liquidity will also depend on the financial performance of the Company’s leased facilities and the facilities managed by CJM Advisors, including Autumn Breeze, Georgetown, Glenvue, Mountain Trace, Southland and Sumter, as well as the performance of the Pharmacy Services business. In addition, the Real Estate Services segment consists of leases to one operator. Aspire Regional Partners, through a group of affiliated tenants, leases five facilities. The Company therefore depends on tenants affiliated with Aspire for all of its rent revenues, and there can be no assurance that such tenants will have sufficient assets, income or access to financing to enable them to make rental payments or otherwise satisfy their lease obligations.

Long-term Liquidity

Management expects that the Company’s long-term liquidity needs will be funded primarily from cash generated in the ordinary course of business and, as needed, from the sale of securities. The Company’s ability to generate cash from operations on a long-term basis will depend on the operating performance of its Healthcare Services, Pharmacy Services and Real Estate Services segments, including occupancy, reimbursement levels, labor costs, pharmacy reimbursement collections, rent collections and overall operating margins.

The Company’s ability to raise capital through the sale of securities will depend on market conditions, investor interest, the trading price and liquidity of its securities and its overall financial performance. Because the Company’s securities trade on the OTCQB rather than a national securities exchange, access to equity capital may be more limited than that of issuers listed on a national securities exchange. Accordingly, there can be no assurance that long-term liquidity from the sale of securities will be available on acceptable terms, if at all.

Debt

As of September 30, 2026, the Company had $42.2 million in indebtedness, net of $0.8 million deferred financing costs and unamortized discounts. The Company anticipates net principal repayments of approximately $7.9 million during the next twelve-month period, approximately $4.0 million of routine debt service amortization, $0.2 million payment of bond debt, and $3.7 million of Southland's maturing debt.

Debt Covenant Compliance

At September 30, 2026, the Company was in compliance with the various financial and administrative covenants related to all of the Company's credit facilities, except with respect to the Southland-related USDA and SBA notes that are subject to the forbearance arrangements. Management continues to monitor compliance closely and evaluate refinancing and other liquidity alternatives.

Evaluation of the Company's Ability to Continue as a Going Concern

Under the accounting guidance related to the presentation of financial statements, the Company is required to evaluate, on a quarterly basis, whether or not the Company's current financial condition, including its sources of liquidity at the date that the consolidated financial statements are issued, will enable the Company to meet its obligations as they come due arising within one year of the date of the issuance of the Company's consolidated financial statements and to make a determination as to whether or not it is probable, under the application of this accounting guidance, that the Company will be able to continue as a

15


 

going concern. The Company's consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

In performing this evaluation, management considered the Company’s current financial condition and liquidity sources, including unrestricted cash, forecasted future cash flows, anticipated collections of receivables, expected refinancing activity, expected debt borrowings, anticipated proceeds from assets held for sale and the Company’s obligations due within the next twelve months, together with recurring operating expenses. Based on this evaluation, management concluded that it is probable that the Company will be able to meet its obligations arising within one year after the date these consolidated financial statements are issued.

NOTE 3. BUSINESS COMBINATION

 

On August 14, 2025, the Company completed its merger with SunLink Health Systems, Inc. (“SunLink”), pursuant to which SunLink merged with and into the Company, with the Company continuing as the surviving corporation. The merger was accounted for as a business combination in accordance with Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”), with the Company identified as both the legal acquirer and the accounting acquirer. Upon completion of the merger, SunLink ceased to exist as a separate legal entity.

 

Purchase Price Allocation

 

The unaudited consolidated financial information reflects a gain on bargain purchase because the estimated fair value of the identifiable net assets acquired exceeds the estimated purchase price consideration.

 

At the closing, 1,595,400 Shares of Regional Health common stock and 1,405,609 Regional Series D preferred stock were converted and issued. The Regional Health common stock at the merger was valued at the closing trading on the closing date. The new Regional Health Series D preferred stock was valued by an independent valuation firm. The total value of the Regional equity exchanged for the SunLink shares, were based on the following shares (in thousands, except share amounts):

Share type Shares Price per share Total

Common 1,595,400 $1.98 $3,159

Preferred D 1,405,609 $3.34 $4,691

Total consideration transferred to SunLink holders $7,850

For the three and nine months ended September 30, 2025, a gain on bargain purchase of $5,311 thousand was recognized for the merger because the fair value of identifiable net assets exceeded the purchase price consideration. A summary of the fair value consideration transferred for the Merger and the preliminary allocation to the fair value of the assets and liabilities of SunLink follows:

16


 

(Amounts in 000’s)

 

 

 

September 30,
2025

 

Regional common stock issued to SunLink shareholders

$

3,159

 

Regional Series D preferred stock issued to SunLink shareholders

 

4,691

 

Fair value of consideration transferred

 

7,850

 

Property and equipment, net

 

3,159

 

Cash

 

5,975

 

Receivables, net

 

2,853

 

Prepaids and other assets

 

874

 

Inventory

 

1,402

 

Intangible assets

 

2,010

 

ROU operating lease assets

 

593

 

Estimated fair value of total assets acquired

 

16,866

 

Accounts Payable

 

1,032

 

Operating lease obligation

 

594

 

Accrued expenses and other liabilities

 

2,079

 

Fair value of total

 

3,705

 

Fair value of net assets acquired

 

13,161

 

Loss (gain) on bargain purchase

$

(5,311

)

 

The above preliminary purchase price allocation was based on an evaluation of the appropriate fair values and represented management's best estimate on the available data at that time. Changes within the measurement period resulting from facts and circumstances that existed as of the acquisition date resulted in retrospective adjustments to the provisional amounts recorded at the acquisition date.

 

Acquisition-related costs (included in other expense in the Company's Consolidated Statements of Operations and comprehensive income (loss)) were $584 thousand and $1,201 thousand for the three and nine months periods ended September 30, 2025, respectively.

 

For the three and nine months ended September 30, 2026, the company recorded a purchase price adjustment of $78 thousand, related to prepaid expenses.

For further details regarding the Company's merger with SunLink, see Note 3 - Business Combination in Part I, Item 1, Financial Statements and Supplementary Data, included in the Annual Report.

 

NOTE 4. CASH AND RESTRICTED CASH

The following presents the Company's cash and restricted cash:

(Amounts in 000’s)

 

September 30,
2026

 

 

December 31,
2025

 

Cash

 

$

1,651

 

 

$

3,013

 

Restricted cash:

 

 

 

 

 

 

Cash collateral

 

 

118

 

 

 

61

 

HUD and other replacement reserves

 

 

1,983

 

 

 

1,463

 

Escrow deposits

 

 

824

 

 

 

1,210

 

Restricted cash for debt obligations

 

 

317

 

 

 

317

 

Total restricted cash

 

 

3,242

 

 

 

3,051

 

Total cash and restricted cash

 

$

4,893

 

 

$

6,064

 

Cash collateral—In securing mortgage financing from certain lending institutions, the Company and certain of its wholly-owned subsidiaries are required to deposit cash to be held as collateral in accordance with the terms of such loan agreements.

17


 

HUD and other replacement reserves—The regulatory agreements entered into in connection with the financing secured through HUD require monthly escrow deposits for replacement and improvement of the HUD project assets.

Escrow deposits—In connection with financing secured through the Company's lenders, several wholly-owned subsidiaries of the Company are required to make monthly escrow deposits for taxes and insurance.

Restricted cash for debt obligations—In compliance with certain financing and insurance agreements, the Company and certain wholly-owned subsidiaries of the Company are required to deposit cash held as collateral by the lender or in escrow with certain designated financial institutions.

NOTE 5. PROPERTY AND EQUIPMENT

The following table sets forth the Company's property and equipment:

(Amounts in 000’s)

 

Estimated
Useful
Lives (Years)

 

September 30,
2026

 

 

December 31,
2025

 

Buildings and improvements

 

5-40

 

$

51,354

 

 

$

51,069

 

Equipment and computer related

 

2-10

 

 

5,296

 

 

 

4,354

 

Land

 

—

 

 

2,343

 

 

 

2,330

 

Property and equipment

 

 

 

 

58,993

 

 

 

57,753

 

Less: accumulated depreciation

 

 

 

 

(23,968

)

 

 

(21,948

)

Property and equipment, net

 

 

 

$

35,025

 

 

$

35,805

 

The following table summarizes total depreciation and amortization expense for the three and nine months ended September 30, 2026 and 2025:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

(Amounts in 000’s)

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Depreciation

 

$

671

 

 

$

454

 

 

$

1,924

 

 

$

1,073

 

Amortization

 

 

114

 

 

 

93

 

 

 

340

 

 

 

278

 

Total depreciation and amortization expense

 

$

785

 

 

$

547

 

 

$

2,264

 

 

$

1,351

 

 

NOTE 6. ASSETS HELD FOR SALE

During the three months ended September 30, 2026, the Company reassessed the fair value less costs to sell of Meadowood in accordance with ASC 360. On October 27, 2026, the Company received a nonbinding letter of intent from a prospective purchaser proposing a purchase price of approximately $4.0 million for the property and related operating business. Management evaluated the letter of intent under ASC 855 and concluded that it provided additional evidence of conditions existing as of September 30, 2026. The valuation assumptions were based on the three-level hierarchy for fair value measurement and represent Level 2 inputs.

 

Based on the anticipated purchase price of approximately $4.0 million, less estimated selling costs of $0.2 million, the Company determined fair value less costs to sell of approximately $3.8 million. Accordingly, the Company recognized an impairment loss of approximately $0.5 million during the three and nine months ended September 30, 2026. The impairment loss is included in operating expenses in the accompanying condensed consolidated statements of operations.

 

The following table sets forth the Company's assets held for sale by asset description:

 

18


 

(Amounts in 000's)

 

Lives (Years)

 

September 30,
2026

 

 

December 31,
2025

 

Buildings and improvements

 

5 - 40

 

$

5,281

 

 

$

5,218

 

Equipment and computer related

 

2 - 10

 

 

459

 

 

 

459

 

Land

 

—

 

 

100

 

 

 

100

 

 

 

 

 

5,840

 

 

 

5,777

 

Less: accumulated depreciation and
   amortization

 

 

 

 

(1,570

)

 

 

(1,570

)

Less: impairment loss on assets held for sale

 

 

 

 

(459

)

 

 

—

 

Assets held for sale, net

 

 

 

$

3,811

 

 

$

4,207

 

The following table sets for the Company's assets held for sale by facility:

(Amounts in 000's)

 

 

September 30,
2026

 

 

December 31,
2025

 

Meadowood

 

 

 

3,811

 

 

 

4,207

 

Assets held for sale, net

 

 

 

$

3,811

 

 

$

4,207

 

 

NOTE 7. INTANGIBLE ASSETS AND GOODWILL

Intangible assets and Goodwill consist of the following:

(Amounts in 000’s)

 

Bed licenses
(included
in property and
equipment)
(1)

 

 

Bed Licenses -
Separable
(2)

 

 

Lease
Rights

 

 

Pharmacy Intangibles

 

 

Total

 

 

Pharmacy Intangibles - Trade Name (2)

 

 

Goodwill (2)

 

Balances, December 31, 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross

 

$

11,796

 

 

$

2,471

 

 

$

176

 

 

$

1,430

 

 

$

15,873

 

 

$

740

 

 

$

1,585

 

Accumulated amortization

 

 

(4,880

)

 

 

—

 

 

 

(124

)

 

 

(33

)

 

 

(5,037

)

 

 

—

 

 

 

—

 

Net carrying amount

 

$

6,916

 

 

$

2,471

 

 

$

52

 

 

$

1,397

 

 

$

10,836

 

 

$

740

 

 

$

1,585

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances, September 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross

 

$

11,796

 

 

$

2,471

 

 

$

176

 

 

$

1,430

 

 

$

15,873

 

 

$

740

 

 

$

1,585

 

Accumulated amortization

 

 

(5,144

)

 

 

—

 

 

 

(137

)

 

 

(96

)

 

 

(5,377

)

 

 

—

 

 

 

—

 

Net carrying amount

 

$

6,652

 

 

$

2,471

 

 

$

39

 

 

$

1,334

 

 

$

10,496

 

 

$

740

 

 

$

1,585

 

(1)
Non-separable bed licenses are included in property and equipment as is the related accumulated amortization expense (see Note 5 – Property and Equipment).
(2)
The Company does not amortize indefinite-lived intangibles, which consist of separable bed licenses, trade names, and goodwill.

The following table summarizes amortization expense for the three and nine months ended September 30, 2026 and 2025:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

(Amounts in 000’s)

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Bed licenses

 

$

88

 

 

$

89

 

 

$

264

 

 

$

265

 

Lease rights

 

 

4

 

 

 

4

 

 

 

13

 

 

 

13

 

Pharmacy Intangibles

 

 

22

 

 

 

—

 

 

 

63

 

 

 

—

 

Total amortization expense

 

$

114

 

 

$

93

 

 

$

340

 

 

$

278

 

 

19


 

Expected amortization expense for the years ending December 31, for all definite-lived intangibles, for the remaining three months ending December 31, 2026 and each of the next four years and thereafter is as follows:

(Amounts in 000’s)

 

Pharmacy Intangibles

 

 

Bed
Licenses

 

 

Lease
Rights

 

For the remaining three months ending December 31, 2026

 

$

22

 

 

$

88

 

 

$

4

 

2027

 

 

88

 

 

 

352

 

 

 

18

 

2028

 

 

88

 

 

 

352

 

 

 

17

 

2029

 

 

88

 

 

 

352

 

 

 

—

 

2030

 

 

88

 

 

 

352

 

 

 

—

 

Thereafter

 

 

960

 

 

 

5,156

 

 

 

—

 

Total expected amortization expense

 

$

1,334

 

 

$

6,652

 

 

$

39

 

 

NOTE 8. LEASES

Operating Leases

As of September 30, 2026 and December 31, 2025, the Company leases one Skilled Nursing Facility ("SNF") in Covington, Ohio under a non-cancelable lease, which has rent escalation clauses and provisions for payments of real estate taxes, insurance, and maintenance costs. The remaining lease term for the Covington facility is approximately 2.3 years as of September 30, 2026. The Company subleases the Covington facility to a third party.

The Company subleases certain office space located in Atlanta, Georgia, which will expire on July 31, 2027.

The Pharmacy Segment business assets at the Merger included $593 thousand of Right of Use assets, consisting primarily of four non-cancellable property leases with expiration dates ranging from July 2027 to March 2031 and office equipment leases. As of September 30, 2026, the Company's total Right of Use asset balance was $2.8 million and is a part of the Company's Other assets balance of $3.5 million. As of December 31, 2025, the Company's total Right of Use asset balance was $2.9 million and is a part of the Company's Other assets balance of $3.8 million.

As of September 30, 2026, the Company is in compliance with all operating lease financial covenants.

Future Minimum Lease Payments

Future minimum lease payments for the twelve months ending December 31, for the remaining three months ending December 31, 2026 and each of the next four years and thereafter is as follows:

(Amounts in 000’s)

 

Future
rental
payments

 

 

Accretion of
lease liability
(1)

 

 

Operating
lease
obligation

 

For the remaining three months ending December 31, 2026

 

$

283

 

 

$

(42

)

 

$

241

 

2027

 

 

1,076

 

 

 

(124

)

 

 

952

 

2028

 

 

998

 

 

 

(66

)

 

 

932

 

2029

 

 

546

 

 

 

(17

)

 

 

529

 

2030

 

 

313

 

 

 

(5

)

 

 

308

 

Thereafter

 

 

65

 

 

 

(1

)

 

 

64

 

Total

 

$

3,281

 

 

$

(255

)

 

$

3,026

 

(1)
Weighted average discount rate 7.98% and weighted average remaining term 3 years.

Facilities Leased or Subleased by the Company

On February 1, 2026, the Company terminated the lease with C-Ross for the Autumn Breeze facility. We have subsequently entered into a management agreement with CJM Advisors to provide day-to-day management services.

As of September 30, 2026, five facilities (four owned by Regional and one leased to Regional) are leased or subleased on a triple net basis, meaning that the lessee (i.e., the third-party operator of the property, or the Company with respect to the operated facilities) is obligated under the lease or sublease, as applicable, for all liabilities of the property in respect to

20


 

insurance, taxes and facility maintenance, as well as the lease or sublease payments, as applicable. As of September 30, 2026, all facilities are operated by Aspire Regional Partners.

Future Minimum Lease Receivables

Future minimum lease receivables for the twelve months ending December 31, for the remaining three months ending December 31, 2026 and each of the next four years and thereafter is as follows:

(Amounts in 000’s)

 

Lease Receivables

 

For the remaining three months ending December 31, 2026

 

$

787

 

2027

 

 

3,167

 

2028

 

 

2,924

 

2029

 

 

—

 

2030

 

 

—

 

Thereafter

 

 

—

 

Total

 

$

6,878

 

For further details regarding the Company's leased and subleased facilities to third-party operators, including a full summary of the Company's leases to third-parties and which comprise the future minimum lease receivables of the Company, see Note 8 - Leases and Leasing Transactions in Part I, Item 1, Financial Statements and Supplementary Data, included in the Annual Report.

NOTE 9. ACCRUED EXPENSES

Accrued expenses consist of the following:

(Amounts in 000’s)

 

September 30,
2026

 

 

December 31,
2025

 

Accrued employee benefits and payroll-related

 

$

2,181

 

 

$

1,637

 

Real estate and other taxes

 

 

6,622

 

 

 

5,032

 

Accrued interest

 

 

176

 

 

 

189

 

Other accrued expenses (1)

 

 

813

 

 

 

1,030

 

Total accrued expenses

 

$

9,792

 

 

$

7,888

 

 

(1) As of September 30, 2026 and December 31, 2025, the remaining escheatment liabilities for discontinued operations are $0.3 million and are included in other accrued expenses.

 

NOTE 10. NOTES PAYABLE AND OTHER DEBT

Entry into Forbearance Agreements

On February 27, 2026, the Company and Erin Property Holdings, LLC (the “Borrower”) entered into two Forbearance Agreements with effective dates of February 1, 2026 (the “Forbearance Agreements”) with Cadence Bank, N.A. (the “Lender”) relating to certain defaults by the Company and the Borrower under the loan agreements in the principal amount of $5,000,000 due on July 27, 2036 (the “USDA Note”) and the principal amount of $800,000 due on July 27, 2036 (the “SBA Note” and, together with the USDA Note, the “Notes”) that were issued by the Borrower to the Company to reflect payment obligations pursuant to the Security Agreement, dated as of July 27, 2011 (the “Security Agreement”), between the Borrower and the Lender.

Pursuant to the Forbearance Agreements, (a) the Borrower agreed to make payments of $21,047.76 as a one-time forbearance payment and $6,764.21 for the 2026 USDA annual renewal fee toward the SBA Note no later than February 27, 2026, and (b) the Company and the Lender agreed, subject to the terms and conditions set forth in the Forbearance Agreements, to forbear from exercising its rights and remedies on account of the failure by the Company and the Borrower to pay the amounts due under the USDA Note and SBA Note by the expiration of the period (“Forbearance Period”) of February 1, 2027.

During the Forbearance Period, the Company and the Borrower shall make monthly payments of principal and interest in

21


 

accordance with the terms of the USDA Note and the SBA Note with interest continuing to accrue in accordance with the terms of the Notes which amounts shall remain the obligation of the Company and the Borrower.

The remaining balances of the USDA Note and the SBA Note will be due at the end of the Forbearance Period and include all principal, interest, late charges and statutory attorney's fees.

See Note 10 – Notes Payable and Other Debt in Part II, Item 8, Financial Statements and Supplementary Data, included in the Annual Report for a detailed description of all the Company's debt facilities.

Notes payable and other debt consists of the following:

(Amounts in 000’s)

 

September 30,
2026

 

 

December 31,
2025

 

Senior debt—guaranteed by HUD

 

$

26,612

 

 

$

27,281

 

Senior debt—guaranteed by USDA (1)

 

 

6,276

 

 

 

6,575

 

Senior debt—guaranteed by SBA(2)

 

 

487

 

 

 

509

 

Senior debt—bonds

 

 

5,638

 

 

 

5,811

 

Senior debt—other mortgage indebtedness

 

 

3,027

 

 

 

2,979

 

Other debt

 

 

927

 

 

 

805

 

Subtotal

 

 

42,967

 

 

 

43,960

 

Deferred financing costs

 

 

(680

)

 

 

(706

)

Unamortized discount on bonds

 

 

(96

)

 

 

(101

)

Notes payable and other debt

 

$

42,191

 

 

$

43,153

 

(1)
U.S. Department of Agriculture (USDA)
(2)
U.S. Small Business Administration (SBA)

The following is a detailed listing of the debt facilities that comprise each of the above categories:

(Amounts in 000’s)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Facility

 

Lender

 

Maturity

 

Interest Rate (1)

 

 

September 30,
2026

 

 

December 31,
2025

 

Senior debt - guaranteed by HUD (2)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The Pavilion Care Center

 

Newpoint Capital

 

12/01/2039

 

Fixed

 

 

3.97

%

 

$

697

 

 

$

727

 

Hearth and Care of Greenfield

 

Newpoint Capital

 

08/01/2050

 

Fixed

 

 

3.97

%

 

 

1,792

 

 

 

1,825

 

Woodland Manor

 

Newpoint Capital

 

11/01/2052

 

Fixed

 

 

3.97

%

 

 

4,629

 

 

 

4,703

 

Glenvue

 

Newpoint Capital

 

10/01/2044

 

Fixed

 

 

3.75

%

 

 

6,427

 

 

 

6,611

 

Autumn Breeze

 

KeyBank

 

01/01/2045

 

Fixed

 

 

3.65

%

 

 

5,593

 

 

 

5,751

 

Georgetown

 

Newpoint Capital

 

10/01/2046

 

Fixed

 

 

2.98

%

 

 

2,847

 

 

 

2,923

 

Sumter Valley

 

KeyBank

 

01/01/2047

 

Fixed

 

 

3.70

%

 

 

4,627

 

 

 

4,741

 

Total

 

 

 

 

 

 

 

 

 

 

$

26,612

 

 

$

27,281

 

Senior debt - guaranteed by USDA (3)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Mountain Trace

 

Community B&T

 

12/24/2036

 

Prime + 1.75%

 

 

8.75

%

 

 

3,050

 

 

 

3,193

 

Southland

 

Cadence Bank, NA

 

07/27/2036

 

Prime + 1.50%

 

 

8.50

%

 

 

3,226

 

 

 

3,382

 

Total

 

 

 

 

 

 

 

 

 

 

$

6,276

 

 

$

6,575

 

Senior debt - guaranteed by SBA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Southland(4)

 

Cadence Bank, NA

 

07/27/2036

 

Prime + 2.25%

 

 

9.25

%

 

 

487

 

 

 

509

 

Total

 

 

 

 

 

 

 

 

 

 

$

487

 

 

$

509

 

 

(1)
Represents interest rates as of September 30, 2026 as adjusted for interest rate floor limitations, if applicable. The rates exclude amortization of deferred financing costs which are approximately 0.16% per annum.

22


 

(2)
For the seven SNF’s, the Company has term loans insured 100% by HUD with financial institutions. The loans are secured by, among other things, an assignment of all rents paid under any existing or future leases and rental agreements with respect to the underlying facility. The loans contain customary events of default, including fraud or material misrepresentations or material omission, the commencement of a forfeiture action or proceeding, failure to make required payments, and failure to perform or comply with certain agreements. Upon the occurrence of certain events of default, the lenders may, after receiving the prior written approval of HUD, terminate the loans and all amounts under the loans will become immediately due and payable. In connection with entering into loans, the facilities entered into a healthcare regulatory agreement and a promissory note, each containing customary terms and conditions.
(3)
For the two SNF’s, the Company has term loans with financial institutions, which are insured 70% to 80% by the USDA. The loans have an annual renewal fee for the USDA guarantee of 0.25% of the guaranteed portion. The loans have prepayment penalties of 1% through 2020, capped at 1% for the remainder of the first 10 years of the term and 0% thereafter.
(4)
For one SNF, commonly known as Southland, the Company has a term loan with a financial institution, which is insured 75% by the SBA.

 

(Amounts in 000’s)

 

 

 

 

 

 

 

 

 

 

 

 

Facility

 

Lender

 

Maturity

 

Interest Rate (1)

 

September 30, 2026

 

December 31, 2025

Senior debt - bonds

 

 

 

 

 

 

 

 

 

 

 

 

Eaglewood Bonds Series A

 

City of Springfield, Ohio

 

05/01/2042

 

Fixed

 

7.65%

 

$5,638

 

$5,811

(1)
Represents cash interest rates as of September 30, 2026. The rates exclude amortization of deferred financing of approximately 0.10% per annum.

(Amounts in 000’s)

 

 

 

 

 

 

 

 

 

 

 

 

Facility

 

Lender

 

Maturity

 

Interest Rate (1)

 

September 30,
2026

 

December 31,
2025

Senior debt - other mortgage indebtedness

 

 

 

 

 

 

 

 

Meadowood (2)

 

Exchange Bank of Alabama

 

10/01/2026

 

Fixed

 

4.50%

 

$2,844

 

$2,979

Meadowood - Line of Credit

 

Exchange Bank of Alabama

 

02/15/2027

 

Fixed

 

6.75%

 

183

 

—

Total

 

 

 

 

 

 

 

 

 

$3,027

 

$2,979

(1)
Represents cash interest rates as of September 30, 2026 as adjusted for interest rate floor limitations, if applicable. The rates exclude amortization of deferred financing costs of 0.34% per annum.
(2)
The Meadowood Credit Facility is secured by the Meadowood Facility, which is guaranteed by Regional Health Properties, Inc. (See Note 15. Subsequent Events)

 

(Amounts in 000’s)

 

 

 

 

 

 

 

 

 

 

 

 

 

Lender

 

Maturity

 

Interest Rate

 

 

September 30,
2026

 

 

December 31,
2025

 

Other debt

 

 

 

 

 

 

 

 

 

 

 

 

 

First Insurance Funding (1)

 

09/15/2027

 

Fixed

 

 

10.95

%

 

$

179

 

 

$

254

 

AFCO Insurance

 

08/09/2026

 

Fixed

 

 

9.50

%

 

 

—

 

 

 

34

 

Cavalier Senior Living

 

11/15/2026

 

Fixed

 

 

6.00

%

 

 

7

 

 

 

22

 

First Horizon Bank

 

02/24/2031

 

Fixed

 

 

7.25

%

 

 

246

 

 

 

—

 

Key Bank (2)

 

08/25/2030

 

Fixed

 

 

0.00

%

 

 

495

 

 

 

495

 

Total

 

 

 

 

 

 

 

 

$

927

 

 

$

805

 

(1)
Annual Insurance financing primarily for the Company's directors and officers insurance.

23


 

(2)
On December 30, 2022, Key Bank and the Company extended the maturity date from August 25, 2025 to August 25, 2030.

Debt Covenant Compliance

As of September 30, 2026, the Company had 17 credit related instruments outstanding that include various financial and administrative covenant requirements. Covenant requirements include, but are not limited to, fixed charge coverage ratios, debt service coverage ratios, minimum earnings before interest, taxes, depreciation, and amortization or earnings before interest, taxes, depreciation, amortization, and restructuring or rent costs, and current ratios. Certain financial covenant requirements are based on consolidated financial measurements whereas others are based on measurements at the subsidiary level (i.e., facility, multiple facilities or a combination of subsidiaries). The subsidiary level requirements are as follows: (i) financial covenants measured against subsidiaries of the Company; and (ii) financial covenants measured against third-party operator performance. Some covenants are based on annual financial metric measurements, whereas others are based on monthly and quarterly financial metric measurements. The Company routinely tracks and monitors its compliance with its covenant requirements.

As of September 30, 2026, the Company was in compliance with the various financial and administrative covenants related to all of the Company’s credit facilities, except with respect to the Southland-related USDA and SBA notes that are subject to the forbearance arrangements.

Scheduled Maturities

The schedule below summarizes the scheduled gross maturities as of September 30, 2026 for the remaining three months ending December 31, 2026 and each of the next four years and thereafter.

For the Twelve Months Ended December 31,

 

(Amounts in 000’s)

 

For the remaining three months ending December 31, 2026

*

$

7,068

 

2027

 

 

1,423

 

2028

 

 

1,428

 

2029

 

 

1,506

 

2030

 

 

2,067

 

Thereafter

 

 

29,475

 

Subtotal

 

$

42,967

 

Less: unamortized discounts

 

 

(96

)

Less: deferred financing costs, net

 

 

(680

)

Total notes and other debt

 

$

42,191

 

 

* Includes amounts previously due from Meadowood that were subsequently refinanced. (See Note 15. Subsequent Events.)

NOTE 11. COMMON AND PREFERRED STOCK

Common Stock

As of September 30, 2026, the Company had 55,000,000 shares of Common Stock authorized and 3,935,557 shares issued and 3,924,677 shares outstanding. There were no dividends declared or paid on the common stock during the three and nine months ended September 30, 2026 and 2025.

Preferred Stock

As of September 30, 2026, the Company had 5,000,000 shares of Preferred Stock authorized and 3,655,721 shares issued and outstanding.

Series A Preferred Stock

As of September 30, 2026, the Company had 560,000 shares of Series A Preferred Stock issued and outstanding. There were no dividends declared or paid on the Series A Preferred Stock for the three and nine months ended September 30, 2026 and 2025.

Series B Preferred Stock

During the nine months ended September 30, 2026, the Company purchased 51,061 shares of its Series B Preferred Stock for a

24


 

cost of $321 thousand under the Company's Stock Repurchase Plan authorized on November 25, 2025.

In January 2025, the board of directors of the Company declared a dividend to the holders of its Series B Preferred Stock, on a pro rata basis in proportion to the number of shares of Series B Preferred Stock held by such holders of 250,000 shares of the Company’s common stock, rounded down to the nearest whole share of Common Stock. The dividend was paid in February 2025 to holders of record of the Series B Preferred Stock as of the close of business on February 10, 2025 and 249,990 shares of the Company's common stock were issued. The Company is required to pay the dividend of Common Stock to such holders of Series B Preferred Stock pursuant to the terms of Regional’s Amended and Restated Articles of Incorporation, which governs the terms of the Series B Preferred Stock.

As of September 30, 2026, the Company had 1,690,112 shares of Series B Preferred Stock issued and outstanding. Except for the dividends declared in January 2025, no other dividends were declared or paid on the Series B Preferred Stock for the three and nine months ended September 30, 2026 and 2025.

Series D Preferred Stock

As of September 30, 2026, the Company had 1,405,609 shares of Series D Preferred Stock issued and outstanding. No dividends were declared or paid on the Series D Preferred Stock for the three and nine months ended September 30, 2026.

See Note 12 – Common and Preferred Stock in Part II, Item 8, Financial Statements and Supplementary Data, included in the Annual Report for more information on our stock.

NOTE 12. STOCK BASED COMPENSATION

On January 5, 2026, the Company's shareholders approved the Regional Health Properties, Inc. Amended and Restated 2023 Omnibus Incentive Compensation Plan (the “A&R Plan”). The A&R Plan (i) increased the number shares of our common stock authorized for issuance under the A&R Plan by 550,000 shares, which increased the total number of authorized shares available for issuance under the A&R Plan to 775,000 and (ii) increased the number of share of our common stock that may be issued pursuant to incentive stock options under the A&R Plan to 775,000. All other terms of the 2023 Omnibus Incentive Compensation Plan remained the same.

Stock Incentive Plans

As of September 30, 2026, the number of securities remaining available for future issuance under the Company's A&R Plan is 351,000.

For the three and nine months ended September 30, 2026 and 2025, the Company recognized stock-based compensation expense as follows:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

(Amounts in 000’s)

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Employee compensation:

 

 

 

 

 

 

 

 

 

 

 

 

Restricted stock awards

 

$

47

 

 

$

124

 

 

$

136

 

 

$

171

 

Restricted stock units

 

 

20

 

 

 

—

 

 

 

52

 

 

 

—

 

Stock options

 

 

18

 

 

 

—

 

 

 

46

 

 

 

—

 

Total employee stock-based compensation expense

 

 

85

 

 

 

124

 

 

 

234

 

 

 

171

 

Non-employee compensation:

 

 

 

 

 

 

 

 

 

 

 

 

Board stock options

 

 

—

 

 

 

—

 

 

 

20

 

 

 

—

 

Total non-employee stock-based compensation expense

 

 

—

 

 

 

—

 

 

 

20

 

 

 

—

 

Total stock-based compensation expense, net of forfeitures

 

$

85

 

 

$

124

 

 

$

254

 

 

$

171

 

 

25


 

Restricted Stock Awards

The following table summarizes the Company's restricted stock awards ("RSAs") activity for the nine months ended September 30, 2026:

 

 

Number of
Shares (000's)

 

 

Weighted Avg.
Grant Date
(per Share)
Fair Value

 

Unvested, December 31, 2025

 

 

185

 

 

$

2.40

 

Vested

 

 

(94

)

 

$

2.50

 

Forfeited

 

 

(10

)

 

$

2.18

 

Unvested, September 30, 2026

 

 

81

 

 

$

2.32

 

No RSAs were granted for the nine months ended September 30, 2026. The remaining unvested shares at September 30, 2026 will vest over the next 0.8 year with $145 thousand in compensation expense recognized over this period.

Restricted Stock Units

The following table summarizes the Company's restricted stock units ("RSUs") activity for the nine months ended September 30, 2026:

 

 

Number of
Shares (000's)

 

 

Weighted Avg.
Grant Date
(per Share)
Fair Value

 

Unvested, December 31, 2025

 

 

—

 

 

$

—

 

Granted

 

 

135

 

 

$

1.29

 

Unvested, September 30, 2026

 

 

135

 

 

$

1.29

 

For the nine months ended September 30, 2026, RSU awards with respect to 135,000 shares of common stock were granted under the A&R Plan, which will vest in two equal annual installments beginning on their first anniversary date. The remaining unvested shares at September 30, 2026 will vest over the next 1.7 years with $123 thousand in compensation expense recognized over this period.

Common Stock Options

The following summarizes the Company's employee stock option activity for the nine months ended September 30, 2026:

 

 

Number of
Shares (000's)

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Fair Value

 

 

Weighted
Average
Remaining
Contractual
Term
(in years)

 

 

Aggregate
Intrinsic
Value (000's)

 

Outstanding, December 31, 2025

 

 

—

 

 

$

—

 

 

$

—

 

 

 

—

 

 

$

—

 

Granted

 

 

153

 

 

$

1.29

 

 

$

1.13

 

 

 

—

 

 

 

 

Forfeited

 

 

(3

)

 

$

1.30

 

 

$

1.10

 

 

 

—

 

 

$

—

 

Outstanding, September 30, 2026

 

 

150

 

 

$

1.29

 

 

$

1.13

 

 

 

9.4

 

 

$

—

 

Vested and exercisable, September 30, 2026

 

 

15

 

 

$

1.30

 

 

$

1.10

 

 

 

9.3

 

 

$

—

 

Vested and expected to vest, September 30, 2026

 

 

150

 

 

$

1.29

 

 

$

1.13

 

 

 

9.4

 

 

$

—

 

For the nine months ended September 30, 2026, stock option awards with respect to 153,000 shares of common stock were granted under the A&R Plan. The remaining unvested shares at September 30, 2026 will vest over the next 1.7 years with $108 thousand in compensation expense recognized over this period.

26


 

The following summarizes the weighted average information on our stock option awards granted using the Black-Scholes option-pricing model inputs for the nine months ended September 30, 2026 and 2025:

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

Dividend yield

 

—%

 

 

—%

 

Expected volatility

 

 

123.44

%

 

—%

 

Risk-free interest rate

 

 

3.91

%

 

—%

 

Expected term (in years)

 

 

5.7

 

 

 

—

 

The following summary information reflects stock options outstanding, vested, and related details as of September 30, 2026:

 

 

Stock Options Outstanding

 

Stock Options Exercisable

Exercise Price

 

Number of
Shares (000's)

 

Weighted
Average
Remaining
Contractual
Term
(in years)

 

Weighted
Average
Exercise
Price

 

Number of
Shares (000's)

 

Weighted
Average
Remaining
Contractual
Term
(in years)

 

Weighted
Average
Exercise
Price

$1.29-$1.30

 

150

 

9.4

 

$1.29

 

15

 

9.3

 

$1.30

 

 

NOTE 13. COMMITMENTS AND CONTINGENCIES

Regulatory Matters

Laws and regulations governing federal Medicare and state Medicaid programs are complex and subject to interpretation. Compliance with such laws and regulations may be subject to future governmental review, audit, investigation and interpretation, as well as significant regulatory action, including fines, penalties and exclusion from certain governmental programs.

As of September 30, 2026, the Company’s facilities that are operated by the Company, leased or subleased to third-party operators, or otherwise managed by third parties were certified by the Centers for Medicare & Medicaid Services (“CMS”) and were operational. Because the Company operates through Healthcare Services, Pharmacy Services and Real Estate Services segments, regulatory exposure may arise directly from the Company’s operated businesses, indirectly through tenant and operator performance at leased facilities, or from legacy matters relating to prior periods of direct operations. Based on information currently available, the Company believes that it is in compliance in all material respects with applicable laws and regulations relating to its current operations, although there can be no assurance that governmental agencies will not reach different conclusions in the future.

Legal Matters

The Company is party to various legal actions and administrative proceedings and is subject to various claims arising in the ordinary course of business, including claims relating to prior direct facility operations, current operated facilities, employment matters, staffing requirements, commercial disputes and other business matters. The Company believes that many of these matters are defensible and intends to defend them vigorously unless settlement is determined to be in the best interests of the Company. However, there can be no assurance that the resolution of any such matters will not have a material adverse effect on the Company’s business, results of operations or financial condition.

In addition, the Company’s tenants and operators conduct business in a highly regulated industry and are subject to continuing state and federal scrutiny, supervision and control. Such scrutiny may include inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. The Company believes that governmental investigations and enforcement activity involving long-term care providers have increased, particularly in areas involving Medicare and Medicaid reimbursement, false claims, staffing requirements and quality-of-care matters. Adverse determinations in legal proceedings or governmental investigations involving the Company, its prior operations, or its tenants and operators could have a material adverse effect on the Company’s business, results of operations and financial condition.

 

27


 

Professional and General Liability Claims Covered by Insurance

As of September 30, 2026, the Company was a defendant in one professional and general liability action arising from care provided to a former patient at one of the Company's facilities. The complaint alleges, among other things, negligence, including alleged failures to provide adequate and competent staffing, and seeks unspecified actual, compensatory, and punitive damages for alleged injuries, pain and suffering, mental anguish, and malnutrition. The Company intends to vigorously defend this matter and believes that any losses, other than punitive damages, if awarded, would be covered by applicable insurance, subject to the terms, conditions, deductibles, and coverage limits of the applicable insurance policies. Punitive damages, if awarded, are not covered by the Company's insurance policies.

The Company evaluates this matter in accordance with ASC 450, Contingencies. Based on the information currently available, management has concluded that a loss is not probable; therefore, no liability has been accrued as of September 30, 2026. While an unfavorable outcome is reasonably possible, the Company is unable to estimate the amount or range of reasonably possible loss, if any, in excess of available insurance coverage due to the inherent uncertainties associated with litigation.

NOTE 14. SEGMENT RESULTS

The chief operating decision maker (“CODM”) is the President and Chief Executive Officer. The Company represents four reportable segments, based on how its CODM evaluates the business and allocates resources. The CODM assesses performance for the Company and decides how to allocate resources based on each segments Income (Loss) From Operations ("Operating Income"). The CODM uses Operating Income to evaluate the performance of each segment in deciding whether to reinvest profits into the segment. The CODM evaluates performance based on Operating Income, as noted in the table below. The Company reports segment information based on the "significant expense principle” defined in ASC 280, Segment Reporting along with other segment items, which is the difference between segment revenue and less segment expenses disclosed under the significant expense principle for each reported measure of segment profit or loss.

The Company has four primary reporting segments: (i) Corporate, which consists of general and administrative expenses, (ii) Real Estate Services, which consists of the leasing and subleasing of long-term care and senior living facilities to third-party tenants, (iii) Healthcare Services, which consists of the operation of the Autumn Breeze, Georgetown, Glenvue, Meadowood, Sumter, Southland, and Mountain Trace facilities and (iv) Pharmacy Service Segment, which consists of four operational areas, retail pharmacy products and services, institutional pharmacy services, which consists of specialty and non-specialty pharmaceutical and products to institutional clients or to patients in institutional settings, non-institutional pharmacy services consisting of the provision specialty and non-specialty pharmacy and biological products to clients or patients in non-institutional settings including private residential homes and durable medical equipment, consisting primarily of the sale and rental products for institutional clients or to patients and institutional settings and patient-administered home care.

The table below presents the results of operations for our reporting segments for the periods presented.

28


 

 

Three Months Ended September 30,

 

 

Three Months Ended September 30,

 

 

2026

 

2026

 

2026

 

2026

 

2026

 

 

2025

 

2025

 

2025

 

2025

 

2025

 

(Amounts in 000’s)

Corporate

 

Real Estate Services

 

Healthcare Services

 

Pharmacy Services

 

Total

 

 

Corporate

 

Real Estate Services

 

Healthcare Services

 

Pharmacy Services

 

Total

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Patient care revenues

$

—

 

$

—

 

$

14,714

 

$

—

 

$

14,714

 

 

$

—

 

$

—

 

$

9,831

 

$

—

 

$

9,831

 

Rental revenues

 

—

 

 

785

 

 

—

 

 

13

 

 

798

 

 

 

—

 

 

1,303

 

 

—

 

 

—

 

 

1,303

 

Pharmacy revenues

 

—

 

 

—

 

 

—

 

 

9,502

 

 

9,502

 

 

 

—

 

 

—

 

 

—

 

 

4,004

 

 

4,004

 

Total revenues

 

—

 

 

785

 

 

14,714

 

 

9,515

 

 

25,014

 

 

 

—

 

 

1,303

 

 

9,831

 

 

4,004

 

 

15,138

 

Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

—

 

 

—

 

 

—

 

 

5,838

 

 

5,838

 

 

 

—

 

 

—

 

 

—

 

 

2,470

 

 

2,470

 

Patient care expense

 

—

 

 

—

 

 

11,035

 

 

—

 

 

11,035

 

 

 

—

 

 

—

 

 

8,168

 

 

471

 

 

8,639

 

Facility rent expense

 

—

 

 

149

 

 

—

 

 

99

 

 

248

 

 

 

—

 

 

149

 

 

6

 

 

42

 

 

197

 

Depreciation and amortization

 

—

 

 

319

 

 

108

 

 

358

 

 

785

 

 

 

—

 

 

322

 

 

85

 

 

140

 

 

547

 

General and administrative expense

 

874

 

 

123

 

 

2,401

 

 

3,172

 

 

6,570

 

 

 

755

 

 

234

 

 

1,779

 

 

945

 

 

3,713

 

Credit loss expense

 

—

 

 

—

 

 

210

 

 

—

 

 

210

 

 

 

—

 

 

—

 

 

166

 

 

—

 

 

166

 

Total expenses, excluding impairment

 

874

 

 

591

 

 

13,754

 

 

9,467

 

 

24,686

 

 

 

755

 

 

705

 

 

10,204

 

 

4,068

 

 

15,732

 

Impairment loss on assets held for sale

 

—

 

 

459

 

 

—

 

 

—

 

 

459

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

Income (loss) from operations

$

(874

)

$

(265

)

$

960

 

$

48

 

$

(131

)

 

$

(755

)

$

598

 

$

(373

)

$

(64

)

$

(594

)

 

 

 

Nine Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2026

 

2026

 

2026

 

2026

 

2026

 

 

2025

 

2025

 

2025

 

2025

 

2025

 

(Amounts in 000’s)

Corporate

 

Real Estate Services

 

Healthcare Services

 

Pharmacy Services

 

Total

 

 

Corporate

 

Real Estate Services

 

Healthcare Services

 

Pharmacy Services

 

Total

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Patient care revenues

$

—

 

 

—

 

$

41,430

 

$

—

 

$

41,430

 

 

$

—

 

$

—

 

$

24,247

 

$

—

 

$

24,247

 

Rental revenues

 

—

 

 

2,417

 

 

—

 

 

42

 

 

2,459

 

 

 

—

 

 

4,134

 

 

—

 

 

—

 

 

4,134

 

Pharmacy revenues

 

—

 

 

—

 

 

—

 

 

26,729

 

 

26,729

 

 

 

—

 

 

—

 

 

—

 

 

4,004

 

 

4,004

 

Total revenues

 

—

 

 

2,417

 

 

41,430

 

 

26,771

 

 

70,618

 

 

 

—

 

 

4,134

 

 

24,247

 

 

4,004

 

 

32,385

 

Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

—

 

 

—

 

 

—

 

 

16,419

 

 

16,419

 

 

 

—

 

 

—

 

 

—

 

 

2,470

 

 

2,470

 

Patient care expense

 

—

 

 

—

 

 

31,404

 

 

—

 

 

31,404

 

 

 

—

 

 

—

 

 

19,753

 

 

471

 

 

20,224

 

Facility rent expense

 

—

 

 

446

 

 

—

 

 

283

 

 

729

 

 

 

—

 

 

440

 

 

69

 

 

43

 

 

552

 

Depreciation and amortization

 

—

 

 

956

 

 

312

 

 

996

 

 

2,264

 

 

 

—

 

 

967

 

 

244

 

 

140

 

 

1,351

 

General and administrative expense

 

2,825

 

 

571

 

 

6,993

 

 

9,396

 

 

19,785

 

 

 

2,084

 

 

637

 

 

4,709

 

 

945

 

 

8,375

 

Loss on lease termination

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

303

 

 

—

 

 

—

 

 

303

 

Credit loss expense

 

—

 

 

13

 

 

594

 

 

—

 

 

607

 

 

 

—

 

 

199

 

 

437

 

 

—

 

 

636

 

Gain on operations transfer

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

(106

)

 

—

 

 

(106

)

Total expenses, excluding impairment

 

2,825

 

 

1,986

 

 

39,303

 

 

27,094

 

 

71,208

 

 

 

2,084

 

 

2,546

 

 

25,106

 

 

4,069

 

 

33,805

 

Impairment loss on assets held for sale

 

—

 

 

459

 

 

—

 

 

—

 

 

459

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

Income (loss) from operations

$

(2,825

)

$

(28

)

$

2,127

 

$

(323

)

$

(1,049

)

 

$

(2,084

)

$

1,588

 

$

(859

)

$

(65

)

$

(1,420

)

 

29


 

The CODM does not regularly review total assets for our reportable segments as total assets are not used to assess performance or allocate resources.

NOTE 15. SUBSEQUENT EVENTS

On October 1, 2026, the Company repurchased 4,000 shares of its Series B Preferred shares.

On October 1, 2026, Meadowood Property Holdings, LLC refinanced the existing mortgage with Exchange Bank of Alabama in the amount of $3,026,659. The mortgage shall bear interest at a rate of 6.99 percent and matures on October 5, 2031. Beginning on November 5, 2026, Meadowood Property Holdings, LLC shall make 59 principal and interest payments of $27,217 and 1 balloon payment of $2,371,674 at maturity.

On October 27, 2026, the Company received a nonbinding letter of intent from a prospective purchaser proposing to acquire the Meadowood property and related operating business for approximately $4.0 million. The Company intends to proceed with the proposed transaction and anticipates completing the sale before December 31, 2026, subject to execution of a definitive purchase agreement and customary closing conditions. The Company considered the proposed transaction in its September 30, 2026 impairment assessment, as further discussed in Note 6 — Assets Held for Sale.

In October 2026, the Company became aware of a motion for supplemental proceedings filed on October 2, 2026, in the Court of Common Pleas for Sumter County, South Carolina, relating to a judgment against a former third-party operator of a skilled nursing facility owned by a subsidiary of the Company. The motion seeks to hold the Company, certain subsidiaries, and certain current and former directors and officers, among others, jointly and severally liable for the $26.0 million default judgment (including $15.0 million in punitive damages, together with post-judgment interest) against the former third-party operator under veil-piercing, alter-ego, and related theories. The default judgment was entered against the former third-party operator, not against the Company or its subsidiaries. The Company intends to vigorously defend the matter. At this preliminary stage, the ultimate outcome cannot be determined, and the Company is unable to reasonably estimate the amount or range of any potential loss.

The Company has evaluated all subsequent events through the date the consolidated financial statements were issued and filed with the SEC. There were no other material subsequent events to September 30, 2026.

 

30


 

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward Looking Statements

This Quarterly Report and certain information incorporated herein by reference contain forward-looking statements and information within the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This information includes assumptions made by, and information currently available to management, including statements regarding future economic performance and financial condition, liquidity and capital resources, and management's plans and objectives. In addition, certain statements included in this Quarterly Report, in the Company's future filings with the SEC, in press releases, and in oral and written statements made by us or with our approval, which are not statements of historical fact, are forward-looking statements.

Words such as "may," "could," "should," "would," "believe," "expect," "anticipate," "estimate," "intend," "seek," "plan," "project," "continue," "predict," "will," and other words or expressions of similar meaning are intended by us to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company's current expectations about future events or results and information that is currently available to us, involve assumptions, risks, and uncertainties, and speak only as of the date on which such statements are made.

All forward-looking statements are subject to the risks and uncertainties inherent in predicting the future. The Company's actual results may differ materially from those projected, stated or implied in these forward-looking statements as a result of many factors, including the Company's critical accounting policies and risks and uncertainties related to, but not limited to, the operating results of the Company's tenants, the overall industry environment, and the Company's financial condition. These and other risks and uncertainties are described in more detail in the Annual Report and in Part II, Item 1A "Risk Factors" of this Quarterly Report, as well as other reports that the Company files with the SEC.

Forward-looking statements speak only as of the date they are made and should not be relied upon as representing the Company's views as of any subsequent date. The Company undertakes no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by applicable laws, and you are urged to review and consider disclosures that the Company makes in this Quarterly Report and other reports that the Company files with the SEC that discuss factors germane to the Company's business.

Overview

Regional Health Properties, Inc. is a healthcare company that owns, operates and invests in healthcare real estate and operating businesses focused on long-term care, senior housing and pharmacy services. Historically, the Company operated primarily as a healthcare real estate platform that leased skilled nursing and senior housing facilities to third-party operators under long-term triple-net lease arrangements. Over time, and particularly following recent strategic initiatives and acquisitions, the Company has evolved toward a more integrated owner-operator model that combines healthcare real estate ownership with the direct operation of healthcare facilities and related healthcare services.

As of September 30, 2026 the Company had investments of approximately $60.6 million in healthcare real estate, operated or leased a portfolio consisting primarily of skilled nursing facilities and senior housing communities located in five states, and operates a pharmacy business located in Louisiana, which was acquired following the SunLink merger completed on August 14, 2025.

The Company operates through four reportable segments: Corporate, Healthcare Services, Pharmacy Services and Real Estate Services. The Healthcare Services segment includes the direct operation of skilled nursing and senior housing communities that provide a range of healthcare and residential services, including sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative therapy, memory care, Alzheimer’s and dementia care, and senior living services. The Pharmacy Services segment includes retail pharmacy products and services, institutional pharmacy services and durable medical equipment. The Real Estate Services segment consists of investments in skilled nursing and senior housing properties that are leased or subleased to third-party operators under triple-net lease arrangements. These segments reflect the Company’s evolution from a healthcare landlord into a more diversified healthcare company with both real estate and operating capabilities.

The comparability of the Company’s results for the three months ended September 30, 2026 and 2025 is affected by the SunLink merger, which added the Pharmacy Services segment beginning on August 14, 2025. In addition, one facility that was included in the Real Estate Services segment in 2025 transitioned to the Healthcare Services segment on February 1, 2026. As a

31


 

result, year-over-year comparisons reflect not only changes in operating performance, but also a meaningful change in segment composition. These changes resulted in increased patient care revenues and patient care expenses in Healthcare Services, the addition of pharmacy revenues and related cost of goods sold in Pharmacy Services, and lower rental revenues in Real Estate because one property is no longer operated under a lease structure. Accordingly, the Company’s consolidated and segment results for the three and nine months ended September 30, 2026 are not directly comparable to the prior-year period.

The Company funds its business and its four reportable segments primarily through operating cash flow, collections of patient, pharmacy and rent receivables, mortgage and other debt financing, asset sales and, when available, proceeds from the sale of securities.

Key Segment Operating Metrics

Management evaluates the performance of the Company’s business using selected operating and financial metrics that management believes are most relevant to each of the Company's four reportable segments.

Healthcare Services

The most important operating metrics for the Healthcare Services segment are occupancy/census, payor mix, labor costs, and accounts receivable collections. Management believes these measures are the primary drivers of patient care revenue, operating margins and cash flow for the facilities the Company operates directly.

Occupancy and census are key indicators of demand and facility utilization. Management also monitors payor mix, including the relative percentage of Medicare, Medicaid, managed care and private-pay residents, because reimbursement rates and margins vary significantly by payor source. In addition, labor costs, including wage rates, agency staffing usage and employee benefit costs, are critical measures of operating performance given the labor-intensive nature of skilled nursing and senior housing operations. Management also closely monitors patient accounts receivable and collection trends, as increases in patient receivables can materially affect the segment’s working capital and liquidity.

Pharmacy Services

The most important operating metrics for the Pharmacy Services segment are script count, reimbursement collections, gross margin, and customer retention. Management believes these measures are the best indicators of the scale, profitability and cash-generation profile of the pharmacy business.

Script count is a key measure of pharmacy volume and operating activity. Management also monitors reimbursement collections and the timing of payment from government and commercial payors, because reimbursement levels and collection timing directly affect revenue realization and working capital. Gross margin is an important measure of the relationship between pharmacy revenues and the cost of pharmaceutical products sold or medical equipment rented. Customer retention is also a significant operating measure because the stability of institutional and retail customer relationships affects recurring revenue and the long-term growth of the segment.

Real Estate Services

The most important operating metrics for the Real Estate Services segment are rent collections, tenant credit quality, lease performance, and portfolio optimization opportunities. Management believes these measures are the most relevant indicators of the segment’s recurring cash flow and asset value. Rent collections are a primary measure of current segment performance because rental income remains the principal source of revenue within the Real Estate Services segment. Management also monitors tenant credit quality and the financial performance of operators, as tenant distress or weak facility performance can affect rent collections, lease renewals and the recoverability of receivables. In addition, management evaluates lease restructurings, lease terminations and transition opportunities to determine whether a property is best held as a leased asset, transferred to another operator, or operated directly within the Healthcare Services segment. These evaluations are an important part of the Company’s broader portfolio optimization and owner-operator strategy.

Corporate

The most significant operating metric for the Corporate segment is general and administrative expenses, which primarily consist of corporate personnel costs, professional fees, insurance, information technology, and other administrative expenses. Management believes these costs are key indicators of corporate overhead and the Company's ability to efficiently support its operating segments.

32


 

Management monitors general and administrative expenses to evaluate spending trends, identify opportunities for cost efficiencies, and assess the overall level of corporate overhead relative to the Company's consolidated operations. Particular emphasis is placed on personnel costs, legal and accounting fees, insurance expenses, and other recurring corporate expenditures. Management also evaluates fluctuations in these expenses, including nonrecurring costs associated with acquisitions, financing activities, and other corporate initiatives, to assess their impact on the Company's consolidated operating results.

Recent Activities

Entry into Forbearance Agreements

On February 27, 2026, the Company and Erin Property Holdings, LLC (the “Borrower”) entered into two Forbearance Agreements with effective dates of February 1, 2026 (the “Forbearance Agreements”) with Cadence Bank, N.A. (the “Lender”) relating to certain defaults by the Company and the Borrower under the loan agreements in the principal amount of $5,000,000 due on July 27, 2036 (the “USDA Note”) and the principal amount of $800,000 due on July 27, 2036 (the “SBA Note” and, together with the USDA Note, the “Notes”) that were issued by the Borrower to the Company to reflect payment obligations pursuant to the Security Agreement, dated as of July 27, 2011 (the “Security Agreement”), between the Borrower and the Lender.

Pursuant to the Forbearance Agreements, (a) the Borrower agreed to make payments of $21,047.76 as a one-time forbearance payment and $6,764.21 for the 2026 USDA annual renewal fee toward the SBA Note no later than February 27, 2026, and (b) the Company and the Lender agreed, subject to the terms and conditions set forth in the Forbearance Agreements, to forbear from exercising its rights and remedies on account of the failure by the Company and the Borrower to pay the amounts due under the USDA Note and SBA Note by the expiration of the period (“Forbearance Period”) of February 1, 2027.

During the Forbearance Period, the Company and the Borrower shall make monthly payments of principal and interest in accordance with the terms of the USDA Note and the SBA Note with interest continuing to accrue in accordance with the terms of the Notes which amounts shall remain the obligation of the Company and the Borrower.

The remaining balances of the USDA Note and the SBA Note will be due at the end of the Forbearance Period and include all principal, interest, late charges and statutory attorney's fees.

Segment Reporting

Management believes the most meaningful way to understand 2026 results is by reference to the Company’s four reportable segments together with the consolidated statement of operations and comprehensive earnings. Healthcare Services results reflect the direct operation of facilities, including the impact of taking back operations at certain properties during 2026. Pharmacy Services results reflect the contribution from the pharmacy business acquired in the SunLink merger. Real Estate results reflect rental income, credit loss expense and lease-related activity associated with facilities that remained leased or subleased to third-party operators. Corporate results primarily reflect general and administrative expenses, including corporate personnel costs, professional fees, insurance, information technology, and other administrative costs incurred to support the Company's consolidated operations.

At the consolidated level, patient care revenues, pharmacy revenues and patient care expense increased significantly in 2026 due primarily to the expanded Healthcare Services segment and the addition of Pharmacy Services, while rental revenues declined as certain facilities were transitioned out of the Real Estate Services segment and into operated status. Accordingly, line-item changes in the consolidated statement of operations and comprehensive loss should be evaluated in light of these changes in segment composition.

Real Estate Portfolio

As of September 30, 2026, we had investments of approximately $60.6 million in a portfolio of twelve healthcare facilities, consisting of eleven owned properties and one leased facility. Our owned properties consisted of nine skilled nursing facilities and two senior housing communities. Of the twelve facilities, five were leased or subleased to third-party operators under triple-net lease arrangements, and seven were managed on the Company’s behalf by two external managers. The Company’s leased facility is subleased to a third-party operator under a triple-net lease arrangement.

Skilled nursing facilities. SNFs provide services that include daily nursing, therapeutic rehabilitation, social services, activities, housekeeping, nutrition, medication management and administrative services for individuals requiring certain assistance for

33


 

activities in daily living. A typical skilled nursing facility includes mostly one and two bed units, each equipped with a private or shared bathroom and community dining facilities.

Independent Living Communities

Independent living communities are age-restricted residential communities designed for seniors who are able to live independently but prefer the security, convenience and social setting of community living. These communities typically offer lifestyle services and limited support services for residents who do not require a high level of daily care.

Assisted Living Facilities

Assisted living facilities provide assistance with activities of daily living while allowing residents to maintain a degree of independence. Services commonly include meals, housekeeping, medication reminders, personal care support and other services that help residents live in a supportive residential setting.

Memory Care Communities

Memory care communities provide specialized care for individuals suffering from Alzheimer’s disease and other forms of dementia. These communities typically operate in a more secure setting and offer staff, programming and care plans specifically designed to address cognitive impairment and memory loss.


Portfolio

The following table provides summary information regarding the number of facilities and related licensed beds/units as of September 30, 2026:

Location

 

Owned Skilled Nursing Facilities

 

Leased Skilled Nursing Facilities

 

Owned Senior Housing Facilities

 

Total Properties

Alabama(a)

 

0

 

0

 

1

 

1

Georgia

 

3

 

0

 

0

 

3

North Carolina

 

1

 

0

 

0

 

1

Ohio(b)

 

3

 

1

 

1

 

5

South Carolina

 

2

 

0

 

0

 

2

 

 

9

 

1

 

2

 

12

 

 

 

 

 

 

 

 

 

Location

 

Owned Skilled Nursing Beds/Units

 

Leased Skilled Nursing Beds/Units

 

Owned Senior Housing Beds/Units

 

Total Beds/Units

Alabama(a)

 

0

 

0

 

90

 

90

Georgia

 

395

 

0

 

0

 

395

North Carolina

 

106

 

0

 

0

 

106

Ohio(b)

 

185

 

75

 

95

 

355

South Carolina

 

180

 

0

 

0

 

180

 

 

866

 

75

 

185

 

1,126

 

 

 

 

 

 

 

 

 

Location

 

Owned Skilled Nursing Investment

 

Leased Skilled Nursing Investment

 

Owned Senior Housing Investment

 

Total Investment

Alabama(a)

 

—

 

—

 

$5,839,228

 

$5,839,228

Georgia

 

21,706,392

 

—

 

—

 

21,706,392

North Carolina

 

7,459,064

 

—

 

—

 

7,459,064

Ohio(b)

 

8,446,216

 

84,265

 

6,716,420

 

15,246,901

South Carolina

 

10,395,337

 

—

 

—

 

10,395,337

 

 

$48,007,009

 

$84,265

 

$12,555,648

 

$60,646,922

 

(a) Meadowood Retirement Village offers assisted living, memory care, and independent living.

(b) Eaglewood Village offers assisted living and Eaglewood Care Center offers skilled nursing.

 

34


 

The following table provides summary information regarding the number of facilities and related licensed beds/units by operator/manager affiliation as of September 30, 2026:

Operator Affiliation

 

Number of Facilities (1)

 

Beds / Units

Aspire Regional Partners

 

5

 

355

    Subtotal

 

5

 

355

Manager Affiliation

 

Number of Facilities (1)

 

Beds / Units

CJM Advisors

 

6

 

681

Cavalier Senior Living

 

1

 

90

    Subtotal

 

7

 

771

Total

 

12

 

1,126

(1)
Represents the number of owned facilities leased or subleased to separate tenants, of which each tenant is an affiliate of the entity named in the table above.

For a more discussion of the above information, see Note 8 – Leases to the consolidated financial statements included in Part I, Item 1 herein. Additionally, see "Portfolio of Healthcare Investments" included in Part I, Item 1 "Business" in the Annual Report.

Portfolio Occupancy Rates

The following table provides summary information regarding our portfolio facility-level occupancy rates for the periods shown:

 

 

Operating Metric

December 31, 2025

 

March 31, 2026

 

June 30, 2026

 

September 30, 2026

Occupancy (%)

73.2%

 

73.2%

 

74.9%

 

76.0%

Lease Expiration

The following table provides summary information regarding our lease expirations for the years shown as of December 31,:

 

 

Licensed Beds

Annual Lease Revenue

 

Number of Facilities

Count

Percent

Amount ($)
'000's
(1)

Percent (%)

2028

5

355

100.0%

2,839

100.0%

Total

5

355

100.0%

2,839

100.0%

(1)
Straight-line rent.

35


 

Results of Operations

The following table sets forth, for the periods indicated, an unaudited statement of operations and comprehensive loss items and the amounts and percentages of change of these items. The results of operations for any particular period are not necessarily indicative of results for any future period. The following data should be read in conjunction with our consolidated financial statements and the notes thereto, which are included herein.

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

(Amounts in 000’s)

2026

 

 

2025

 

 

Percent
Change

 

 

2026

 

 

2025

 

 

Percent
Change

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Patient care revenues

$

14,714

 

 

$

9,831

 

 

 

49.7

%

 

$

41,430

 

 

$

24,247

 

 

 

70.9

%

Rental revenues

 

798

 

 

 

1,303

 

 

 

(38.8

)%

 

 

2,459

 

 

 

4,134

 

 

 

(40.5

)%

Pharmacy revenues

 

9,502

 

 

 

4,004

 

 

 

137.3

%

 

 

26,729

 

 

 

4,004

 

 

 

567.6

%

Total revenues

 

25,014

 

 

 

15,138

 

 

 

65.2

%

 

 

70,618

 

 

 

32,385

 

 

 

118.1

%

Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

5,838

 

 

 

2,470

 

 

 

136.4

%

 

 

16,419

 

 

 

2,470

 

 

 

564.7

%

Patient care expense

 

11,035

 

 

 

8,639

 

 

 

27.7

%

 

 

31,404

 

 

 

20,224

 

 

 

55.3

%

Facility rent expense

 

248

 

 

 

197

 

 

 

25.9

%

 

 

729

 

 

 

552

 

 

 

32.1

%

Depreciation and amortization

 

785

 

 

 

547

 

 

 

43.5

%

 

 

2,264

 

 

 

1,351

 

 

 

67.6

%

General and administrative expense

 

6,570

 

 

 

3,713

 

 

 

76.9

%

 

 

19,785

 

 

 

8,375

 

 

 

136.2

%

Loss on lease termination

 

—

 

 

 

—

 

 

N/M

 

 

 

—

 

 

 

303

 

 

 

(100.0

)%

Credit loss expense

 

210

 

 

 

166

 

 

 

26.5

%

 

 

607

 

 

 

636

 

 

 

(4.6

)%

Gain on operations transfer

 

—

 

 

 

—

 

 

N/M

 

 

 

—

 

 

 

(106

)

 

 

(100.0

)%

Total expenses, excluding impairment

 

24,686

 

 

 

15,732

 

 

 

56.9

%

 

 

71,208

 

 

 

33,805

 

 

 

110.6

%

Impairment loss on assets held for sale

 

459

 

 

 

—

 

 

 

100.0

%

 

 

459

 

 

 

—

 

 

 

100.0

%

Income (loss) from operations

 

(131

)

 

 

(594

)

 

 

(77.9

)%

 

 

(1,049

)

 

 

(1,420

)

 

 

(26.1

)%

Other (income) expense:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

576

 

 

 

751

 

 

 

(23.3

)%

 

 

1,665

 

 

 

2,019

 

 

 

(17.5

)%

Gain on bargain purchase

 

78

 

 

 

(5,311

)

 

 

(101.5

)%

 

 

78

 

 

 

(5,311

)

 

 

(101.5

)%

Loss on disposal of fixed assets

 

11

 

 

 

—

 

 

 

100.0

%

 

 

19

 

 

 

—

 

 

 

100.0

%

Other (income) expense, net

 

83

 

 

 

584

 

 

 

(85.8

)%

 

 

80

 

 

 

1,201

 

 

 

(93.3

)%

Total other (income) expense, net

 

748

 

 

 

(3,976

)

 

 

(118.8

)%

 

 

1,842

 

 

 

(2,091

)

 

 

(188.1

)%

Net income (loss)

$

(879

)

 

$

3,382

 

 

 

(126.0

)%

 

$

(2,891

)

 

$

671

 

 

 

(530.8

)%

 

For the three and nine months ended September 30, 2026, total revenues increased to $25.0 million and $70.6 million, respectively, from $15.1 million and $32.4 million for the same prior-year periods, primarily due to the addition of Pharmacy Services revenues following the SunLink merger and increased Healthcare Services revenues from facilities transitioned to operated status. Total expenses also increased as the Company incurred the related cost of goods sold, patient care expenses and general and administrative expenses associated with the expanded operating platform. Net loss for the three and nine months ended September 30, 2026 was $0.9 million and $2.9 million, respectively, from the net income of $3.4 million and $0.7 million for the same prior-year periods, primarily from the gain on bargain purchase from the SunLink merger recorded on August 14, 2025.

Three Months Ended September 30, 2026 and 2025

Patient care revenues—Patient care revenues were $14.7 million for the three months ended September 30, 2026, compared to $9.8 million for the same period in 2025. The 49.7% increase is due to the transition of the Autumn Breeze, Georgetown, and Sumter facilities to the Healthcare Services segment and to a lesser extent an increase in census at our Glenvue facility.

36


 

Rental revenues—Rental revenue decreased by approximately $0.5 million to $0.8 million for the three months ended September 30, 2026, compared with $1.3 million for the same period in 2025. The 38.8% decrease is primarily due to transition of the Autumn Breeze, Georgetown and Sumter facilities to our Healthcare Services segment.

Pharmacy revenue— Pharmacy revenues were $9.5 million for the three months ended September 30, 2026, compared to $4.0 million for the same period in 2025. These revenues reflect the Pharmacy Services segment added in connection with the SunLink merger. For the three months ended September 30, 2025, the Pharmacy Revenue only represents revenue earned after the merger with SunLink on August 14, 2025.

Cost of goods sold—Cost of goods sold was $5.8 million for the three months ended September 30, 2026, compared to $2.5 million for the same period in 2025. These costs reflect the cost of pharmacy products sold or rented by the Pharmacy Services segment. For the three months ended September 30, 2025, the cost of goods sold only represents the associated costs on revenue earned after the merger with SunLink on August 14, 2025.

Patient care expense—Patient care expense was $11.0 million for the three months ended September 30, 2026 compared with $8.6 million for the same period in 2025. The current period expense increase of $2.4 million was primarily due to the transition of the Autumn Breeze, Georgetown, and Sumter facilities to the Healthcare Services segment and to a lesser extent an increase in census at our Glenvue facility.

Facility rent expense—Facility rent was $0.2 million for the three months ended September 30, 2026, which was generally consistent for the three months ended September 30, 2025.

Depreciation and amortization—Depreciation and amortization was $0.8 million for the three months ended September 30, 2026, compared to $0.5 million for the same period in 2025. The 43.5% increase was primarily due to depreciation on assets acquired in the SunLink acquisition.

General and administrative expenses—General and administrative expenses were $6.6 million for the three months ended September 30, 2026 compared with $3.7 million for the same period in 2025. The 76.9% increase was primarily due to the transition of the Autumn Breeze, Georgetown, Southland and Sumter facilities to the Healthcare Services segment and the addition of operations acquired in the SunLink merger.

 

Three Months Ended September 30,

 

(Amounts in 000’s)

2026

 

 

2025

 

 

Percent
Change

 

General and administrative expenses:

 

 

 

 

 

 

 

 

Corporate

$

874

 

 

$

755

 

 

 

15.8

%

Real Estate Services

 

123

 

 

 

234

 

 

 

(47.4

)%

Healthcare Services

 

2,401

 

 

 

1,779

 

 

 

35.0

%

Pharmacy

 

3,172

 

 

 

945

 

 

 

235.7

%

Total

$

6,570

 

 

$

3,713

 

 

 

76.9

%

Loss on Lease Termination—There were no expenses related to lease terminations for the three months ended September 30, 2026 and for the same period in 2025.

Credit loss expenses—Credit loss expense was $0.2 million for the three months ended September 30, 2026 and $0.2 million for the same period in 2025. The loss primarily represents reserves taken against patient accounts receivable in the period.

Impairment loss on assets held for sale —During the three months ended September 30, 2026, the Company recognized a noncash impairment loss of approximately $0.5 million related to the Meadowood property, compared to no impairment loss in the prior-year period. The impairment was based on estimated fair value less costs to sell of approximately $3.8 million, as further discussed in Note 6 — Assets Held for Sale.

Loss (gain) on bargain purchase—During the three months ended September 30, 2026, the Company recognized a purchase price adjustment of $78 thousand associated with the SunLink merger. The gain on bargain purchase of $5.3 million for the three months ended September 30, 2025 resulted from the SunLink merger completed on August 14, 2025.

 

37


 

Nine Months Ended September 30, 2026 and 2025

Patient care revenues—Patient care revenues were $41.4 million for the nine months ended September 30, 2026, compared to $24.2 million for the same period in 2025. The 70.9% increase is due to the transition of the Autumn Breeze, Georgetown, and Sumter facilities to the Healthcare Services segment and to a lesser extent an increase in census at our Glenvue facility.

Rental revenues—Rental revenue decreased by $1.7 million to $2.5 million for the nine months ended September 30, 2026, compared with $4.1 million for the same period in 2025. The 40.5% decrease is primarily due to transition of the Autumn Breeze, Georgetown and Sumter facilities to our Healthcare Services segment.

Pharmacy revenue— Pharmacy revenues were $26.7 million for the nine months ended September 30, 2026, compared to $4.0 million for the same period in 2025. These revenues reflect the Pharmacy Services segment added in connection with the SunLink merger. For the nine months ended September 30, 2025, the Pharmacy Revenue only represents revenue earned after the merger with SunLink on August 14, 2025.

Cost of goods sold—Cost of goods sold was $16.4 million for the nine months ended September 30, 2026, compared to $2.5 million for the same period in 2025. These costs reflect the cost of pharmacy products sold or rented by the Pharmacy Services segment. For the nine months ended September 30, 2025, the cost of goods sold only represents the associated costs on revenue earned after the merger with SunLink on August 14, 2025.

Patient care expense—Patient care expense was $31.4 million for the nine months ended September 30, 2026 compared with $20.2 million for the same period in 2025. The current period expense increase of $11.2 million was primarily due to the transition of the Autumn Breeze, Georgetown, and Sumter facilities to the Healthcare Services segment and to a lesser extent an increase in census at our Glenvue facility.

Facility rent expense—Facility rent was $0.7 million for the nine months ended September 30, 2026, which was slightly higher when compared to the nine months ended September 30, 2025, primarily due to the leases acquired in the SunLink merger.

Depreciation and amortization—Depreciation and amortization was $2.3 million for the nine months ended September 30, 2026, compared to $1.4 million for the same period in 2025. The 67.6% increase was primarily due to depreciation on assets acquired in the SunLink acquisition.

General and administrative expenses—General and administrative expenses were $19.8 million for the nine months ended September 30, 2026, compared with $8.4 million for the same period in 2025. The 136.2% increase was primarily due to the transition of the Autumn Breeze, Georgetown, Southland and Sumter facilities to the Healthcare Services segment and the addition of operations acquired in the SunLink merger.

 

Nine Months Ended September 30,

 

(Amounts in 000’s)

2026

 

 

2025

 

 

Percent
Change

 

General and administrative expenses:

 

 

 

 

 

 

 

 

Corporate

$

2,825

 

 

$

2,084

 

 

 

35.6

%

Real Estate Services

 

571

 

 

 

637

 

 

 

(10.4

)%

Healthcare Services

 

6,993

 

 

 

4,709

 

 

 

48.5

%

Pharmacy

 

9,396

 

 

 

945

 

 

 

894.3

%

Total

$

19,785

 

 

$

8,375

 

 

 

136.2

%

 

Loss on Lease Termination—There were no material expenses related to lease terminations for the nine months ended September 30, 2026, compared to $0.3 million for the same period in 2025, which related to the termination of the two leases to Oak Hollow Healthcare Management, and the losses consist of the write-offs of straight-line rent.

Credit loss expenses—Credit loss expense was $0.6 million for the nine months ended September 30, 2026, compared to $0.6 million for the same period in 2025. The loss primarily represents reserves taken against patient accounts receivable in the period.

38


 

Impairment loss on assets held for sale —During the nine months ended September 30, 2026, the Company recognized a noncash impairment loss of approximately $0.5 million related to Meadowood, compared to no impairment loss in the prior-year period. See Note 6 — Assets Held for Sale for additional information.

Gain on operations transfer—There was no gain on operations transfer for the nine months ended September 30, 2026, compared to $0.1 million for the same period in 2025. In March 2025, the Company took patient accounts receivable in lieu of the outstanding Rent Receivable owed by Oak Hollow Healthcare Management as part of the lease termination.

Loss (gain) on bargain purchase—During the nine months ended September 30, 2026, the Company recognized a purchase price adjustment of $78 thousand associated with the SunLink merger. The gain on bargain purchase of $5.3 million for the nine months ended September 30, 2025 resulted from the SunLink merger completed on August 14, 2025.

 

NON-GAAP Financial Measures

The following table summarizes the Company's non-GAAP financial measure of results based on EBITDA for the quarters ending September 30, 2026 and 2025. EBITDA attributable to the Company's financial measure represents net income (loss) before interest expense (including amortization of deferred financing costs), provision for income tax, and depreciation and amortization. Adjusted EBITDA represents EBITDA further adjusted to eliminate the impact of certain items that the Company does not consider indicative of core operating performance, such as recovery of previously reversed rent, amortization of stock-based compensation, lease termination revenue, gains or losses from dispositions of real estate, real estate impairment charges, provision for loan losses, non-routine transaction costs, loss on extinguishment of debt, unrealized loss on other real estate related investments and provision for credit losses and lease restructuring, as applicable.

REGIONAL HEALTH PROPERTIES, INC.

 

RECONCILIATION OF NET LOSS TO NON-GAAP FINANCIAL MEASURES

 

(in thousands)

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Net income (loss)

 

$

(879

)

 

$

3,382

 

 

$

(2,891

)

 

$

671

 

Depreciation and amortization

 

 

785

 

 

 

547

 

 

 

2,264

 

 

 

1,351

 

Interest expense, net

 

 

576

 

 

 

751

 

 

 

1,665

 

 

 

2,019

 

EBITDA

 

 

482

 

 

 

4,680

 

 

 

1,038

 

 

 

4,041

 

Amortization of employee stock compensation

 

 

85

 

 

 

124

 

 

 

254

 

 

 

171

 

Loss (gain) from bargain purchase

 

 

78

 

 

 

(5,311

)

 

 

78

 

 

 

(5,311

)

Loss on disposal of assets

 

 

11

 

 

 

—

 

 

 

19

 

 

 

—

 

Other (income) expense, net

 

 

—

 

 

 

584

 

 

 

—

 

 

 

1,201

 

One-time income adjustment - quality incentive program (1)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(196

)

Tail insurance on legacy facilities

 

 

—

 

 

 

—

 

 

 

—

 

 

 

74

 

Impairment loss on assets held for sale

 

 

459

 

 

 

—

 

 

 

459

 

 

 

—

 

Other one-time costs

 

 

35

 

 

 

170

 

 

 

398

 

 

 

366

 

Adjusted EBITDA from operations

 

$

1,150

 

 

$

247

 

 

$

2,246

 

 

$

346

 

(1) Amounts represent adjustments needed for historical and estimated future amounts along with reconciling for timing differences.

 

 

 

 

 

 

 

Liquidity and Capital Resources

Overview

The Company’s liquidity profile is determined by the operating performance and working capital needs of the Healthcare Services and Pharmacy Services segments, as well as rent collections, tenant performance and refinancing activity within the Real Estate Services segment.

The Company’s primary sources of cash include revenues from its healthcare operations, pharmacy operations, rental income,

39


 

collections of patient, pharmacy and rent receivables, refinancing transactions, debt borrowings and proceeds from asset sales. The Company’s primary uses of cash include salaries, wages and other operating costs of its Healthcare Services and Pharmacy Services segments, facility and rent expenses, debt service, capital expenditures and other working capital needs. Management monitors cash collections, facility-level operating performance, pharmacy reimbursement collections, tenant rent collections, refinancing activity, access to debt markets and access to equity capital as key liquidity drivers. Trading on the OTCQB may limit the Company’s ability to raise equity capital, which could affect future refinancing efforts, growth initiatives and overall financial flexibility.

Short-term Liquidity

Management expects the Company’s short-term liquidity requirements over the twelve months following the filing of this Quarterly Report to be funded primarily through collections of patient accounts receivable, rent receivable and other receivables, mortgage refinancing activity, including the potential refinancing of the Southland facility, additional debt borrowings and proceeds from the sale of assets classified as held for sale. The Company’s short-term liquidity continues to be affected by the transition of the Autumn Breeze facility from leased to operated status, which has increased working capital requirements, including payroll, supplies, patient care costs and patient accounts receivable.

The Company continues to evaluate financing and liquidity alternatives. The Company remains in discussions with potential lenders regarding the refinancing of the Southland facility. In addition, the Company has received a non-binding term sheet for the refinancing of several mortgage loans, which, if completed, could provide additional liquidity for working capital and general corporate purposes. The proposed refinancing remains subject to lender due diligence, credit approval, definitive documentation, third-party reports and other customary closing conditions, and there can be no assurance that any such refinancing will be completed on the terms contemplated, within the expected timeframe, or at all.

The Company continues to evaluate opportunities to monetize non-core assets as part of its capital allocation strategy. The Meadowood facility remained classified as held for sale as of September 30, 2026. During the quarter ended March 31, 2026, the Company engaged a new broker to expand its marketing efforts and facilitate negotiations with prospective purchasers.

On October 27, 2026, the Company received a nonbinding letter of intent from a prospective purchaser proposing to acquire the Meadowood property and related operating business for approximately $4.0 million. The Company anticipates completing the sale before December 31, 2026, subject to execution of a definitive purchase agreement, due diligence, financing, and customary closing conditions.

 

In connection with its assessment of the assets held for sale, the Company recognized a noncash impairment loss of approximately $0.5 million during the three months ended September 30, 2026, resulting in a carrying value of approximately $3.8 million. See Note 6 — Assets Held for Sale for additional information.

 

The timing of the sale and amount of net proceeds remain subject to completion of the transaction and repayment of related indebtedness. There can be no assurance that the sale will be completed on the anticipated terms or within the expected timeframe.

 

During the nine months ended September 30, 2026, the Company generated $2.5 million of cash in operating activities. Operating cash flows were primarily affected by working capital investments associated with the assumption of operations at Autumn Breeze, which was partially offset by non-cash adjustments. Management continues to focus on collections of patient accounts receivable, past due rent and notes receivable. The Company anticipates collecting a portion of past due rent subsequent to quarter end and is negotiating various methods to collect the remaining unpaid rent and notes receivable. However, the timing and amount of collections remain subject to tenant and patient payor performance, reimbursement timing, collection efforts and other factors outside the Company’s control.

 

At September 30, 2026, the Company had $1.7 million in unrestricted cash and $10.6 million of net accounts receivable, mainly consisting of patient accounts receivables.

 

As of September 30, 2026, the Company had $42.2 million in indebtedness, net of $0.8 million of deferred financing costs, and unamortized discounts. The Company anticipates net principal repayments of approximately $7.9 million during the next twelve-month period, consisting of approximately $4.0 million of routine debt service amortization, $0.2 million of bond debt payments, and $3.7 million of Southland's maturing debt.

 

 

 

 

40


 

 

 

Long-term Liquidity

Management expects the Company’s long-term liquidity needs will be funded primarily from cash generated in the ordinary course of business in conjunction with the sale of securities. The Company’s ability to generate long-term liquidity from operations will depend on the operating performance of its Healthcare Services, Pharmacy Services and Real Estate segments, including occupancy, reimbursement levels, labor costs, pharmacy reimbursement collections, rent collections and overall operating margins. The Company’s ability to raise capital through the sale of securities will depend on market conditions, investor interest, the trading price and liquidity of its securities and its overall financial performance. Because the Company’s securities trade on the OTCQB rather than a national securities exchange, access to equity capital may be more limited than that of issuers listed on a national securities exchange.

Debt Covenant Compliance

As of September 30, 2026, the Company was in compliance with the various financial and administrative covenants under all the Company's outstanding credit related instruments, except with respect to the Southland-related USDA and SBA notes that are subject to the forbearance arrangements.

Evaluation of the Company's Ability to Continue as a Going Concern

Under the accounting guidance related to the presentation of financial statements, the Company is required to evaluate, on a quarterly basis, whether or not the Company's current financial condition, including its sources of liquidity at the date that the consolidated financial statements are issued, will enable the Company to meet its obligations as they come due arising within one year of the date of the issuance of the Company's consolidated financial statements and to make a determination as to whether or not it is probable, under the application of this accounting guidance, that the Company will be able to continue as a going concern. The Company's consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. In applying applicable accounting guidance, management considered the Company's current financial condition and liquidity sources, including current funds available, forecasted future cash flows, the Company's obligations due over the next twelve months, and the Company's recurring business operating expenses.

The Company concludes that it is probable that the Company will be able to meet its obligations arising within one year of the date of issuance of these consolidated financial statements within the parameters set forth in the accounting guidance.

For additional information regarding the Company's liquidity, see Note 2 – Liquidity and Note 10 – Notes Payable and other debt, to the consolidated financial statements included in Part I, Item 1 herein.

Cash Flows

The following table presents selected data from our consolidated statements of cash flows for the periods presented:

 

 

Nine Months Ended September 30,

 

(Amounts in 000’s)

 

2026

 

 

2025

 

Net cash provided by (used in) operating activities

 

$

2,496

 

 

$

(994

)

Net cash (used in) provided by investing activities

 

 

(1,568

)

 

 

5,332

 

Net cash used in financing activities

 

 

(2,099

)

 

 

(3,818

)

Net change in cash and restricted cash

 

 

(1,171

)

 

 

520

 

Cash and restricted cash at beginning of period

 

 

6,064

 

 

 

3,472

 

Cash and restricted cash, ending

 

$

4,893

 

 

$

3,992

 

Nine Months Ended September 30, 2026

Net cash provided by (used in) operating activities—was approximately $2.5 million. The positive cash flow from operating activities were primarily affected by working capital investments associated with the assumption of operations at Autumn Breeze and non-cash adjustments.

Net cash (used in) provided by investing activities —was approximately $1.6 million. This capital expenditure was primarily for leasehold improvements.

41


 

Net cash used in financing activities—was approximately $2.1 million. The cash was used to make routine payments totaling $1.3 million for our Senior debt obligations, and $0.7 million for other debt, and cash used for the repurchase of our Series B Preferred Stock was $0.3 million, offset by debt proceeds of $0.3 million.

Nine Months Ended September 30, 2025

Net cash provided by (used in) operating activities—was approximately $1.0 million. The negative cash flow from operating activities was mainly due to the timing of working capital accounts.

Net cash (used in) provided by investing activities—was approximately $5.3 million. This includes $6.0 million of cash acquired in the SunLink merger.

Net cash used in financing activities—was approximately $3.8 million. Cash of $2.7 million was used to repurchase Series B Preferred shares and make routine payments totaling $1.3 million for our senior debt obligations.

Off-Balance Sheet Arrangements

Guarantee

The Company subleased five facilities located in Ohio to the Aspire Sublessees, formerly affiliated with MSTC Development Inc., pursuant to the Aspire Subleases, whereby the Aspire Sublessees took possession of, and commenced operating, the Aspire Facilities as subtenant. The Company agreed to indemnify Aspire against any and all liabilities imposed on them as arising from the former operator, capped at $8.0 million. The Company has assessed the fair value of the indemnity agreements as not material to the financial statements at September 30, 2026. For further information see Note 8 – Leases, to the consolidated financial statements included in Part I, Item 1 herein and also Note 8 – Leases included in Part II, Item 8 of the Annual Report.

Critical Accounting Policies

We prepare our financial statements in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Article 8 of Regulation S-X. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets, liabilities, revenues and expenses. On an ongoing basis, we review our judgments and estimates, including, but not limited to, those related to doubtful accounts, income taxes, stock compensation, intangible assets and loss contingencies. We base our estimates on historical experience, business knowledge and on various other assumptions that we believe to be reasonable under the circumstances at the time. Actual results may vary from our estimates. These estimates are evaluated by management and revised as circumstances change.

For a discussion of our critical accounting policies, see Note 1 – Organization and Significant Accounting Policies to the consolidated financial statements included in Part I, Item 1 herein and also Note 1 – Summary of Significant Accounting Policies included in Part II, Item 8 of the Annual Report.

42


 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Disclosure in response to Item 3 of Form 10-Q is not required to be provided by smaller reporting companies.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report (the "Evaluation Date"). Based on such evaluation, our management has concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting

There has been no change in the Company's internal controls over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

Part II. Other Information

The Company is a defendant in various legal actions and administrative proceedings arising in the ordinary course of business, including claims that the services the Company provided during the time it operated skilled nursing facilities resulted in injury or death to patients. Although the Company settles cases from time to time when settlement can be achieved on a reasonable basis, the Company vigorously defends any matter in which it believes the claims lack merit and the Company has a reasonable chance to prevail at trial or in arbitration. Litigation is inherently unpredictable. There is no assurance that the outcomes of these matters will not have a material adverse effect on the Company's financial condition. Although arising in the ordinary course of the Company's business, certain of these matters are described in Note 13 – Commitments and Contingencies.

Item 1A. Risk Factors.

For a detailed description of certain risk factors that could affect our business, operations and financial condition, see Part I, Item 1A., Risk Factors, included in the Annual Report, as supplemented and modified by the risk factors set forth below in this Item 1A. The risk factors described in the Annual Report and this Quarterly Report (collectively, the “Risk Factors”) do not describe all risks applicable to our business, and we intend it only as a summary of certain material factors. The Risk Factors should be considered in connection with evaluating the forward-looking statements contained in this Quarterly Report because the Risk Factors could cause the actual results and conditions to differ materially from those projected in forward-looking statements. If any of the risks actually occur, our business, financial condition, or results of operations could be negatively affected. In that case, the trading price of the common stock, no par value per share (the "common stock"), the Series A Redeemable Preferred Shares, no par value per share (the "Series A Preferred Stock"), and the 12.5% Series B Cumulative Redeemable Preferred Shares, no par value per share (the "Series B Preferred Stock"), could decline.

There are no material changes to the risk factors set forth in Part I, Item 1A, in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on April 2, 2026.

 

43


 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Issuer Purchases of Equity Securities

During the nine months ended September 30, 2026, the Company purchased 51,061 shares of its 12.5% Series B Cumulative Preferred shares for a total cost of approximately $321 thousand. The shares were funded from cash on hand and were cancelled and returned to the status of authorized but unissued. There were no open-market repurchases of the Company's other securities.

Item 3. Defaults upon Senior Securities.

Entry into Forbearance Agreements

On February 27, 2026, the Company and its subsidiary, Erin Property Holdings, LLC (the “Borrower”) entered into two forbearance agreements with effective dates of February 1, 2026 (the “Forbearance Agreements”) with Cadence Bank, N.A. (the “Lender”) relating to certain defaults under two loan agreements associated with the Company's Southland facility. The loans consist of a loan with an original principal amount of $5,000,000 (the “USDA Note”) and a loan with an original principal amount of $800,000 (the “SBA Note” and, together with the USDA Note, the “Notes”), each with a stated maturity date of July 27, 2036. The Notes are obligations of the Borrower secured pursuant to a Security Agreement dated July 27, 2011, between the Borrower and the Lender.

Pursuant to the Forbearance Agreements, the Lender agreed, subject to the terms and conditions contained therein, to temporarily forbear from exercising certain rights and remedies arising from the existing defaults under the Notes through February 1, 2027 (the “Forbearance Period”). In consideration of the Lender's agreement to forbear, the Borrower agreed to make a one-time forbearance payment of $21,047.76 and a payment of $6,764.21 relating to the 2026 USDA annual renewal fee, each payable no later than February 27, 2026.

 

During the Forbearance Period, the Borrower is required to continue making monthly principal and interest payments in accordance with the terms of the Notes. Interest continues to accrue in accordance with the applicable loan documents, and the Forbearance Agreements do not extinguish the Borrower's obligations under the Notes.

Unless the Notes are refinanced, repaid or otherwise addressed pursuant to an agreement with the Lender, the remaining outstanding amounts under the Notes, including applicable principal, accrued interest, late charges and attorneys' fees, will become due upon expiration of the Forbearance Period. Upon expiration or earlier termination of the Forbearance Period, the Lender may exercise its rights and remedies under the applicable loan documents, subject to their terms and applicable law.

 

The Company continues to evaluate refinancing and other alternatives to address the outstanding obligations under the Notes. There can be no assurance that the Company will successfully complete a refinancing or obtain an extension or other modification of the Forbearance Agreements before the expiration of the Forbearance Period.

 

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Trading Arrangement

During the third quarter of 2026, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408(c) of Regulation S-K of the Securities Act of 1933, as amended).

Item 6. Exhibits.

The agreements included as exhibits to this Quarterly Report are included to provide information regarding the terms of these agreements and are not intended to provide any other factual or disclosure information about the Company, its business or the other parties to these agreements. These agreements may contain representations and warranties by each of the parties to the

44


 

applicable agreement. These representations and warranties have been made solely for the benefit of the other parties to the applicable agreement and:

•
should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;
•
have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;
•
may apply standards of materiality in a way that is different from what may be viewed as material to investors; and
•
were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time, and should not be relied upon by investors.

45


 

EXHIBIT INDEX

Exhibit No.

Description

Method of Filing

3.1

Amended and Restated Articles of Incorporation of Regional Health Properties, Inc., effective July 3, 2023

Incorporated by reference to Exhibit 3.1 of the Registrant's Current Report on Form 8-K filed on July 6, 2023

3.2

Amended and Restated Bylaws of Regional Health Properties, Inc., effective September 21, 2017

Incorporated by reference to Exhibit 3.3 of the Registrant’s Current Report on Form 8-K12B filed on October 10, 2017

3.2(a)

Amendment No. 1 to Amended and Restated Bylaws of Regional Health Properties, Inc., effective June 27, 2023

Incorporated by reference to Exhibit 3.6 of the Registrant’s Post-Effective Amendment No. 1 to Registration Statement on Form S-4 (Reg. No. 333-269750) filed on June 28, 2023

3.2(b)

Articles of Amendment to Amended and Restated Articles of Incorporation of Regional Health Properties, Inc., effective August 5, 2025

Incorporated by reference to Exhibit 3.1 of Registrant's Current Report of Form 8-K filed on August 5, 2025

 

31.1

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act

Filed herewith

31.2

Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act

Filed herewith

32.1

Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act

Filed herewith

32.2

Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act

Filed herewith

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

Filed herewith

101.SCH

Inline XBRL Taxonomy Extension Schema

Filed herewith

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

46


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

REGIONAL HEALTH PROPERTIES, INC.

 

 

 

 

(Registrant)

 

 

 

 

 

Date:

 

November 13, 2026

 

/s/ Brent Morrison

 

 

 

 

Brent Morrison

 

 

 

 

Chairman, Chief Executive Officer, and Director (Principal Executive Officer)

 

 

 

 

 

Date:

 

November 13, 2026

 

/s/ Marlie Davis

 

 

 

 

Marlie Davis

 

 

 

 

Chief Financial Officer (Principal Financial Officer)

 

 

47


Keep reading